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Summary 
The detection and quantification of biologically important blood analytes plays a 
crucial role in the screening, diagnosis and management of disease. However the 
extraction of blood using hypodermic needles brings with it a plethora of issues. Two 
million cases of needle stick injuries in healthcare staff occur annually and 
approximately 10% of adults have needle phobia. Microneedles (MNs) have 
demonstrated potential in the extraction of interstitial fluid (ISF) in a minimally 
invasive manner due to their short length, thus avoiding stimulating pain receptors 
in the skin. ISF contains many of the same analytes that are found in the blood 
including glucose, which is critical in the management of diabetes. However, a large 
proportion of diabetics do not measure their blood glucose levels as often as 
recommended due to the pain and inconvenience of conventional methods. 
Therefore, there is great potential for a minimally invasive MN based approach in the 
extraction and determination of the concentration of glucose within the ISF to 
increase patient compliance and mitigate the negative effects of chronic 
hyperglycaemia.  
Chapter 1 discusses the history of blood diagnostics with a focus on the detection of 
hyperglycaemia in diabetes. The negative consequences of chronic hyperglycaemia 
and the issues with conventional blood glucose determination are discussed. The 
potential of MNs to overcome these issues through indirect measurement of blood 
analytes by sampling ISF is introduced. Chapter 2 details the materials and methods 
used in the experimental chapters.  
Hydrogel forming MNs made from crosslinked polymers have previously 
demonstrated their ability to withdraw ISF containing glucose in human studies. 
Chapter 3 investigates improving the swelling capability of these hydrogel MNs by 
including sodium carbonate in the formulation. A colorimetric glucose sensor is 
developed based on glucose oxidase, horseradish peroxidase and a colour forming 
dye. This sensor is then interfaced with the hydrogel MNs, initially in a hydrogel 
backplate and successfully demonstrates a visually apparent colour change in 
response to the extraction of glucose in simulated ISF in vitro. The time taken for the 
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colour change to occur is substantially decreased by embedding the sensor in a paper 
based backplate and increasing the length of the MN projections. 
Chapter 4 involves the fabrication of a single hollow MN device that can successfully 
withdraw simulated ISF extremely rapidly through capillary action. This device was 
then coupled to the paper based glucose sensor used in Chapter 3. A method to 
quantify the intensity of the colour change on the sensor backplate is developed and 
optimisation of the sensor to produce a linear colour change in response to glucose 
concentration is successfully carried out, thus increasing its potential as diagnostic 
point of care (POC) tool.  
Chapter 5 addresses some of the limitations of the device in Chapter 4 through the 
production of a single metal hollow MN device with a silicone housing that aids the 
flow of fluid from the MN tip and into the paper based sensor backplate through 
suction. The sensor backplate is also modified with an antioxidant to produce an 
“OFF-ON” signal response for the detection of hyperglycaemia within the simulated 
ISF. 
Finally, Chapter 6 contains the conclusions of the results chapters and discusses 
opportunities for further work. 
  
19 
 
Abbreviations 
AA Ascorbic acid 
CAD Computer Aided Design 
ChromB Blue Chromaticity 
GMA Glycidyl Methacrylate 
GOx/HRP Glucose Oxidase/Horseradish Peroxidase 
H2O2 Hydrogen Peroxide 
HA Hyaluronic acid 
MN Microneedle 
NICE National Institute of Clinical Excellence 
OCT Optical Coherence Tomography 
PBS Phosphate Buffered Saline 
PDMS Poly(dimethylsiloxane) 
PEG Poly(ethylene glycol) 
PMVE/MA Poly(Methyl Vinyl Ether-co-Maleic Acid) 
PMVE/MAH Poly(Methyl Vinyl Ether-co-Maleic Anhydride) 
POC Point of Care 
PVA Poly(vinyl alcohol) 
RTV Room Temperature Vulcanising 
SMBG Self-monitoring of blood glucose 
SLA Stereolithographic 
TEGDMA Tri(ethylene glycol) dimethacrylate 
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TMB 3,3′,5,5′-Tetramethylbenzidine 
TPME Tri(propylene glycol) methyl ether 
TRIM Tri(methylolpropane) trimethacrylate 
VAS Visual Analogue Scale 
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Chapter 1 
1.0 Introduction 
1.1 Prologue  
Diagnosis and monitoring of disease through blood analysis is ubiquitous in modern 
healthcare, with the market value for global blood testing in 2015 being $51.5 
billion2. Diabetes is an example of one disease in which frequent blood monitoring is 
essential for decreasing the long term negative effects such as cardiovascular disease 
and stroke as well as avoiding hypoglycaemia which can lead to coma and death. In 
2013, self-monitoring of blood glucose (SMBG) using electronic personal glucometers 
was valued at $3.99 million3.  
Healthcare guidelines recommend SMBG four times daily in Type 1 diabetes and 
insulin dependent Type 2 diabetes, which can be increased up to ten times daily in 
periods of illness or poor control4. However, patient compliance is an issue with 40% 
of Type 1 diabetes performing less SMBG than recommended. This is partially due to 
the pain and inconvenience of blood sampling multiple times daily through the 
conventional method of using a lancet needle to obtain capillary blood on the 
fingertip.  
Microneedles (MNs) are a minimally invasive alternative to conventional needles for 
sampling interstitial fluid (ISF), which has been shown to contain analyte 
concentrations that correlate well to plasma concentrations5,6. Therefore, MNs may 
provide a painless and blood-free method of measuring plasma glucose indirectly and 
replace capillary blood sampling in SMBG, thus increasing patient compliance while 
decreasing the healthcare burden resulting from the long term complications of 
hyperglycaemia. 
Current advancements using MNs for sampling ISF has successfully demonstrated 
glucose responsive insulin delivery7,8, as well as single readings of ISF glucose in 
animals9 and humans10. However, these methods are currently restricted by long 
application times and the requirement of several processing steps post application 
to remove the ISF from the MNs and subsequent determination of the concentration 
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of glucose contained therein. This is time consuming, requires training and is 
therefore unsuitable for a patient Point-of-care (POC) device.  
The work undertaken in this thesis focussed on the development of a MN based 
device designed to rapidly withdraw ISF and determine the concentration of glucose 
via an integrated colorimetric system. Such an approach would enable the potential 
development of a POC device that enables the user to obtain glucose levels within 
the ISF rapidly and without the need for external processing, with the primary goal 
of reducing the incidence of hyperglycaemia in diabetes.  
 
1.2 Blood Diagnostics 
The invention of the compound microscope enabled some of the first scientific 
investigations of blood components. The Dutch microscopist Jan Swammerdan 
described the presence of “red corpuscles” in 1658 (Figure 1.1) which are now 
understood to be erythrocytes or red blood cells11. It was not until over 150 years 
later in 1843 that leukocytes or white blood cells were first reported by Gabriel 
Andral, a French Professor of Medicine, who linked abnormalities in the quantity and 
morphology of the cells to disease12. By the 1880s, microbiologists had isolated 
bacteria from the blood of patients suffering from tuberculosis, cholera, typhoid and 
diphtheria, isolating the organisms responsible for causing disease with the highest 
global mortality rates at that time. However, the antibiotic agents necessary to treat 
these bacterial infections would not be discovered for another 40 years.    
 
Figure 1.1: Illustration of “red corpuscles” of blood by van Leeuwenhoek in 1695, acquaintance of 
Swammerdan. Reproduced from Haju et al.13 
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During the early 20th Century, analytical techniques to identify and quantify chemical 
entities within the urine and blood were developed by clinical chemists. Major strides 
made by Otto Folin between 1904 and 1922 allowed the quantification of urea, 
creatinine, phosphorous and chloride amongst others from the urine alongside 
methods to quantify ammonia and creatinine concentrations in the blood. By 1920, 
venepuncture was in widespread use throughout the world of medicine and clinical 
chemistry in order to obtain blood from patients for analysis. In 1930, Kay reported 
the first clinical laboratory method for the determination of the enzyme alkaline 
phosphatase14 and linked its elevated presence in the blood to Osteitis deformans, 
known as Paget disease in modern medicine, which is characterised by abnormal 
bone growth due to excessive breakdown and formation of bone tissue. This spurred 
investigations into enzymology in clinical laboratories and soon after Cherry and 
Crandall had developed a method to quantify lipase activity in blood serum15. 
Measurement of the common metal cations such as sodium, potassium, calcium and 
magnesium within biological fluids was aided by the introduction of the flame 
photometer in the 1940s16.  Relying on the relatively low excitation energies of the 
Group I and II alkali and alkali earth metals, a flame was used to provide sufficient 
thermal energy to an atomised sample of metal ions in order to raise an electron 
from a lower energy state to a raised excited state17. Electrons in the excited state 
are unstable over time therefore they will return to a lower energy state and the 
subsequent energy released is emitted as visible radiation that can be measured and 
the concentration of the metal cations within the sample can be quantified. 
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Figure 1.2: Results report of Technicon SMA-12 AutoAnalyzer available in 1966 showing multiple 
analyte measurements and reference values simultaneously. Reproduced from Peitzman et al.16 
 
While the flame photometer provided a more convenient and less costly alternative 
to quantify the electrolytes in the serum and urine than the previous methods 
available, which could take between 24 - 48 hours for a single measurement of 
sodium concentration in serum18, integration of flame photometers to automated 
systems provided a revolution in biological electrolyte measurements in the form of 
the AutoAnalyzer manufactured by Technicon during the 1960s. The AutoAnalyzer 
allowed higher throughput of samples and provided a means of measuring multiple 
blood analytes simultaneously (Figure 1.2). 
Modern clinical laboratories in hospitals are able to perform a plethora of blood tests 
in extremely high numbers due to advances in automated systems. Routine blood 
tests include the Basic Metabolic Panel (BMP) also known and Urea and Electrolytes 
and the Comprehensive Metabolic Panel (CMP).  
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The CMP has a total of fourteen analytes and provides information on blood sugar, 
blood proteins, kidney function, liver function, acid/base balance and electrolytes. 
Table 1.1a and 1.1b shows the range of analytes included in the CMP. In 2014, 230 
million biochemistry and 47 million haematology laboratories tests were carried out 
by the NHS in the UK, incurring a cost of £415 million.19   
Table 1.1a Analytes included in CMP and possible indications causing measurements outside of 
reference ranges.20  
Analyte Elevated Levels Indicate Decreased Levels Indicate 
 
Glucose 
Diabetes mellitus, adrenal 
hyperfunction 
 
Excess insulin, hepatic failure, 
starvation, adrenal 
hypofunction 
 
Calcium 
Thyroid and parathyroid 
hyperfunction, bone 
disorders, elevated vitamin 
D, cancers. 
Renal failure, parathyroid 
hypofunction, vitamin D 
deficiency 
 
Sodium 
Dehydration, adrenal 
hyperfunction, renal 
dysfunction, diabetes 
insipidus. 
Renal failure, diuretics, 
overhydration, renal, hepatic 
and heart failure. 
 
Potassium 
Renal failure, adrenal 
hypofunction, acid-base 
imbalance 
Diuretics, diarrhoea, 
vomiting, adrenal 
hypofunction, acid-base 
imbalance 
 
Chloride 
Acid-base imbalance from 
GI, adrenal and renal disease 
Renal disease, adrenal 
hyperfunction, acid-base 
imbalance 
 
Albumin 
n/a Hepatic failure, renal failure, 
malnutrition 
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Table 1.1b Analytes included in CMP and possible indications causing measurements outside of 
reference ranges.20  
Analyte Elevated Levels Indicate Decreased Levels 
Indicate 
Total Protein Chronic infection, 
inflammation, multiple 
myeloma 
 
Malnutrition, hepatic or 
renal failure. 
Blood Urea Nitrogen 
(BUN) 
Renal failure, 
dehydration, GI 
haemorrhage. 
Hepatic failure 
Creatinine Renal failure, 
dehydration 
n/a 
Alkaline Phosphatase Hepatic disease, heart 
failure, parathyroid 
hyperfunction 
n/a 
Alanine Amino 
Transferase 
Hepatic disease n/a 
Aspartate Amino 
Transferase 
Hepatic disease, heart 
injury, muscle injury 
n/a 
 
Total Bilirubin 
Hepatic disease, 
haemolytic anaemia 
 
n/a 
Total CO2 Acid-base imbalance Acid-base imbalance 
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1.3 Diabetes 
Diabetes mellitus is a chronic condition that involves the dysfunctional regulation of 
glucose in the bloodstream. The prevalence of diabetes in adults has increased 
globally since 1980, when 4.7% of the population were diagnosed, to 8.5% of the 
population being diagnosed in 201421. Across the UK, the average prevalence of 
diabetes in adults was 6.0% in 2013. (Table 1.2). 
Table 1.2: Prevalence of diabetes in UK in 2013 broken down by country.22 
Country Prevalence Diabetic Population 
England 6.0% 2,703,044 
Northern Ireland 5.3% 79,072 
Scotland 5.2% 252,599 
Wales 6.7% 173,299 
 
Diabetes can be categorised into several different types according to its aetiology. 
Type 1 diabetes, previously known as insulin dependent or childhood onset diabetes, 
is characterised by a significantly decreased or a total lack of insulin production by 
the pancreas. This is caused by a T cell dependent autoimmune response by the body 
that leads to infiltration of the pancreas by CD4+, CD8 and CD11c+ T cells23 and 
subsequent destruction of islet β cells that are responsible for endogenous insulin 
production24. If left untreated, Type 1 diabetics exhibit symptoms such as excessive 
thirst and urination, constant hunger, weight loss, and vision changes which are all 
due to chronic hyperglycaemia and ketoacidosis25. Without endogenous insulin 
production, Type 1 diabetics require exogenous insulin replacement therapy to 
survive as chronic hyperglycaemia will lead to organ failure, coma and death26.  
The exact cause of Type 1 diabetes is not fully understood27, although it has been 
linked to inherited genetic factors. However, studies of identical twins with Type 1 
diabetes has provided evidence that susceptibility to the disease is not wholly genetic 
indicating that environmental factors also play a role in the pathogenesis of the 
disease28. Among the environmental factors influencing the onset of Type 1 diabetes 
are modulation of the intestinal microbiota in birth by caesarean section, antibiotic 
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use in early stage life29, viral infection with enterovirus30, higher birth weight and 
increased weight gain between the ages of 12 – 18 months31. 
Accounting for approximately 90% of global cases, Type 2 diabetes is the most 
prevalent form of the disease32. Unlike Type 1 disease, the pancreatic islet cells 
remain functional but they fail to compensate for the insulin resistance of the body 
that is caused by increased body mass and adipose tissue33 as well as the 
inflammatory response to hyperglycaemia34. This failure to produce enough 
endogenous insulin, coupled with decreased insulin sensitivity, leads to chronic 
hyperglycaemia that can remain undetected for years until the complications of Type 
2 diabetes manifest themselves.  
Intermediate conditions such as impaired glucose tolerance and impaired fasting 
glycaemia are diagnosed according to the degree of hyperglycaemia found in the 
bloodstream and while they are reversible, patients can progress into the overt 
chronic hyperglycaemia of diabetes, especially Type 2.  
Gestational diabetes occurs in pregnant women who have not previously had 
diabetes but are found to have hyperglycaemia after routine screening, normally at 
28 weeks into the pregnancy35. While it can be a temporary condition that lasts 
throughout the pregnancy, it does increase the long term risk of Type 2 diabetes. A 
meta-analysis of 20 studies carried out on a total of 675,000 pregnant women found 
that women with gestational diagnosed diabetes had a 7.43 fold increased risk (CI 
4.79-11.51) of a subsequent diagnosis of Type 2 diabetes at a later point in life 
compared to women without gestational diabetes36.   
1.4 Hyperglycaemia 
Chronic hyperglycaemia causes damage to the vasculature tissue. It has been 
suggested that the mechanism of this damage is caused by the overproduction of 
reactive oxygen species (ROS) and superoxides by the mitochondria in response to 
hyperglycaemia37 that influences five major metabolic pathways. These are an 
increased flux of glucose and other sugars through the polyol pathway, increased 
intracellular formation of advanced glycation end-products (AGEs), increased 
expression of the receptor for AGEs and its activating ligands, activation of protein 
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kinase C isoforms and over activity of the hexosamine pathway38. Through these 
mechanisms, the action of intracellular ROS is increased, which can cause defective 
angiogenesis in response to ischemia and activate pro-inflammatory pathways, 
leading long term vascular damage39.   
The deleterious effect of hyperglycaemia are commonly separated into 
microvascular and macrovascular complications. Microvascular complications 
include diabetic retinopathy, nephropathy and neuropathy. Macrovascular damage 
leads to coronary artery disease, peripheral artery disease and stroke.  
1.4.1 Microvascular Complications 
1.4.1.1 Diabetic Retinopathy 
Almost all Type 1 diabetics and 58% of Type 2 diabetics develop retinopathy within 
twenty years of diagnosis40. The extent of the retinopathy is correlated to the severity 
of hyperglycaemia and the presence of hypertension41. Early stage background 
retinopathy is indicated by the presence of microaneurysms and small haemorrhages 
of the blood vessels in the middle layers of the retina42. More severe proliferative 
retinopathy involves pathological angiogenesis on the surface of the retina and can 
lead to vitreous haemorrhage and retinal detachment. Vision loss occurs in 25 – 35% 
of high risk cases of proliferative retinopathy43.  
1.4.1.2 Diabetic Nephropathy 
Through a combination of hyperglycaemia and hypertension, progressive loss of 
renal function is observed in 30 – 40% of the diabetic population 25 years after 
diagnosis44. Atrophy of the renal vasculature caused by thickening of the basement 
membrane, interstitial fibrosis and arteriosclerosis leads to microalbuminuria which 
is the presence of elevated levels of albumin in the urine, indicating early stage renal 
damage. Approximately 20% of patients progress to more serious proteinuric 
nephropathy which has a poor prognosis that leads to end stage renal failure and 
cardiac disease45.  
1.4.1.3 Diabetic Neuropathy 
Peripheral nerve dysfunction affects approximately 50% of the diabetic population. 
In distal sensory neuropathy, the most common form that accounts for 80% of 
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diabetic neuropathy cases, typical symptoms experienced include tingling, burning, 
“electric” pain and numbness46. This loss of the protective sensation through 
numbness can increase the risk of peripheral limb injury and infection and can lead 
to diabetic foot ulceration47.  
Diabetic foot ulcers are caused by a combination of neuropathy, peripheral vascular 
disease and minor trauma48 and are the cause of 85% of lower extremity amputations 
in non-traumatic cases49.  
1.4.2 Macrovascular Complications 
While there is strong evidence to suggest that intensive blood glucose control 
decreases the risk of microvascular complications, the evidence that macrovascular 
complications such as stroke and cardiovascular disease are decreased through strict 
glucose control is still debated50. However, the 10 year follow up on the initial UKPDS 
trial in which Type 2 diabetics received intensive glucose lowering therapy compared 
to conventional therapy51 has shown that better glucose control can decrease the 
risk of myocardial infarction by 15% (p = 0.01) and all-cause mortality by 13% (p = 
0.007).  
The underlying cause of the macrovascular complications involves the increased risk 
of atherosclerosis, which is the build-up of a plaque consisting of lipids and fibrous 
elements in the arteries52. This plaque is a result of chronic inflammation of the 
epithelial cells of the vasculature causing an immune response involving monocytes, 
T-lymphocytes, macrophages and mast cells53 and ultimately leads to the narrowing 
of the blood vessels and the propensity for thrombotic formation54. Additionally, 
evidence suggests that there is increased platelet adhesion and increased 
coagulability in Type 2 diabetics55. This further exacerbates the risk of thrombosis 
formation, cardiovascular events and stroke.  In fact, a study on a Finnish diabetic 
population concluded that the risk of myocardial infarction amongst the diabetic 
population was on par with those who had previously experienced myocardial 
infarction56.  
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1.5 Glycaemic Monitoring Requirements 
Single measurements and measurements of long term blood glucose levels are 
routinely monitored in medical settings by healthcare professionals and at home by 
diabetics. In the clinic, the levels of glycated haemoglobin is measured to give an 
indication of the glucose control over a prolonged time period. The measurement of 
glycated haemoglobin is used to determine the average levels of glucose in the blood 
over the previous two to three months57 and is less prone to be affected by short 
term postprandial fluctuations. A component of the haemoglobin (Hb A1c) present 
in erythrocytes, reacts with glucose in the plasma wherein the aldehyde group on 
glucose covalently bonds to the free amine groups present on the peptide chain of 
the Hb A1c forming a Schiff base58. Unlike other specific glycosylation reactions of 
peptides that serve to functionalise them for specific roles, this glycosylation is not 
catalysed enzymatically and, therefore, the rate of reaction is determined by the 
concentration of free glucose in the plasma over the entire course of an erythrocyte’s 
lifespan (approx. 120 days59). In this way, an indication of the average glucose 
concentration over the previous 3-4 months can be obtained. The National Institute 
of Clinical Excellence (NICE) currently recommends that HbA1c should be measured 
every three to six months in persons with Type 1 diabetes and every six months in 
persons with Type 2 diabetes4. The target concentration is 48mmol/mol in most 
diabetics, however, it can vary depending on the treatment regime60. In general, a 
concentration of >75mmol/mol is a sign of hyperglycaemia over a prolonged period 
and would result in a patient being recommended to carry out SMBG up to ten times 
per day to achieve control4.  
The current guidelines by NICE recommend people living with Type 1 diabetes to 
routinely undertake SMBG four times per day, however, it is recommended to check 
as often as ten times per day in periods of poor glucose control, exercise or illness.61 
In Type 2 diabetes, glucose monitoring is a requirement if the person is taking 
hypoglycaemic agents such as sulphonylureas or insulin. Such pharmacological 
agents are given as second or third line interventions when adequate glucose control 
cannot be achieved through lifestyle changes or the use of a first line agent such as 
Metformin. 
32 
 
SMBG by people living with diabetes is commonly performed using an electronic 
glucose meter to obtain a reading of the concentration of glucose within the blood 
at that single point in time. There are many different types of glucose monitors 
available to the public, however, most systems are comprised of a handheld device 
with a display screen. Propriety test strips are inserted into the device and a sample 
of blood is applied to the test strip.  The plasma component of the blood then diffuses 
through an enzyme and electroactive chemical reagent layer that coats an electrode. 
The glucose present in the blood is oxidised by the reagents to produce an electrical 
current which is used to calculate the concentration of glucose via amperometric 
means. Although the exact mechanisms vary between proprietary devices, in most 
cases an electrical current is produced proportional to the amount of glucose present 
in the sample via the reduction of an electroactive chemical such as ferricyanide62. 
When glucose is oxidised by enzymes such as glucose oxidase63, glucose 
dehydrogenase or hexokinase64,65, the ferricyanide present in the strip is reduced to 
ferricyanide and the resulting change in electric potential is measured by the 
electrode. This change is used to calculate the concentration of glucose and is 
displayed to the user.   
The most common method to obtain this blood sample is through the use of a lancet 
needle that can be up to 6 mm long. The needle is inserted into the fingertip via the 
spring-loaded mechanism and a small volume of capillary blood is presented to the 
sample inlet on each test strip. This method has been reported to be inconvenient 
and painful66-68 and leads to compliance issues in the diabetic population. 40% of 
Type 1 diabetics do not undertake SMBG as often as recommended69 and this can 
have negative consequences due to the complications of hyperglycaemia described 
in Section 1.4. Minimally invasive methods to determine the concentration of 
glucose within the plasma through the measurement of ISF have been proposed as 
alternatives70,71 which seek to increase the convenience and decrease the pain 
associated with SMBG, leading to better compliance and long term outcomes for 
people living with diabetes. 
 
33 
 
1.6 Microneedles 
Microneedles (MNs) are an intradermal technology first proposed in in 197672 for the 
purpose of enhancing drug delivery through the skin. The US patent granted to  
Gerstel and Place states that through the aid of a plurality of puncturing projections 
a drug could be percutaneously delivered from a reservoir through the stratum 
corneum and into the epidermis (Figure 1.3).  
 
 
Figure 1.3: Original diagram from Gerstel and Place 1976 patent suggesting use of MN as a drug 
delivery device, showing penetration through the stratum corneum. 
 
However, the technology required to produce the first proof-of-concept device that 
was capable of drug delivery only became widely available in the late 1990’s with the 
rise of microelectronics industry. In 1998, the first publication using MNs to deliver a 
model hydrophilic compound, calcein, through human skin was published by Henry 
et. al73.  
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There have been many subsequent iterations of MNs following this initial application 
by Henry et al., however, MNs can broadly be described as consisting of one or more 
needle-like structures projecting from a supporting baseplate. The needles are 
generally between the length of 25 µm and 2000 µm74 and can be produced in a 
range of 3D geometries including conical, cylindrical, pyramidal and various 2D planar 
designs. Additionally, MNs can be fabricated with a central hollow channel through 
which fluid can pass, similar to a hypodermic needle.  
 
One of the major benefits of MNs are their minimally invasive nature due to their 
small dimensions. The application of MNs is commonly reported to cause little or no 
pain compared to conventional hypodermic needles due to their short length and 
narrow profile, thus avoiding the stimulation of dermal nociceptors75. This will be 
discussed further in Section 1.9. 
 
1.7 Classification of MNs 
Depending on the shape and design, MNs can be classified into a number of different 
categories: solid MNs, coated MNs, dissolving MNs, hollow MNs, and hydrogel 
forming MNs, each of which will be discussed below. 
 
1.7.1 Solid MNs 
Solid MNs can be used as a “pre-treatment” method for skin in order to create pores 
through which a target compound can passively diffuse into the epidermis for local 
action or systemic absorption76. 
Henry et al. produced the first solid MN array from silicon in order to enhance the 
skin permeability of a model fluorescent compound calcein as previously mentioned. 
By mounting human epidermis skin on Franz diffusion cells the transport of the 
fluorescent dye from the donor compartment to the receiver compartment after one 
hour was measured by fluorescent spectroscopy. The ability of the MNs to enhance 
the permeability of the epidermis was then shown by the application of a solid silicon 
20 x 20 MN array with conical MNs approximately 150 µm in length (Figure 1.4) for 
various lengths of time.  
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Figure 1.4: Scanning electron microscope (SEM) images of 20 x 20 solid silicon MN array fabricated by 
Henry et al. 
 
It was found that leaving the MN array in place on the epidermis, the rate of transport 
of the calcein was approximately three orders of magnitude greater than the 
untreated epidermis. When the MN array was applied for ten seconds and then 
removed, the rate of transport was increased by four orders of magnitude and 
subsequently it was shown that by leaving the MN applied for one hour before 
removal, the transport was increased by a further order of magnitude. The suggested 
mechanism of this increase in permeability was due to micropores formed in the 
epidermis by the MN arrays, which was evidenced by examination of the skin sample 
by light microscopy after MN application. Micropores approximately 1 µm in 
diameter were found penetrating the epidermis, thus bypassing the main barrier to 
drug diffusion - the stratum corneum.  
 
McAllister et al.77 have demonstrated fabrication techniques to produce solid MNs 
from a range of materials including silicon, metal, polymers and glass (Figure 1.5). 
Reactive ion etching of a silicon substrate was used to produce large arrays of MNs 
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150 µm in length, while metal arrays were fabricated via electroplating of Ni or NiFe 
on to silicon moulds to produce MNs 120 µm in height. Polyglycolic acid and 
polylactic acid MNs were fabricated using polydimethylsiloxane (PDMS) negative 
moulds and glass MNs were produced using conventional glass micropipette pulling 
apparatus. 
 
 
Figure 1.5:  SEM images of MNs of different morphologies fabricated from various materials - (A-B) 
Silicon (C) Metal (D-F) Polylactic and polyglycolic acid  
 
Oh et al.78 have investigated the use of solid MNs alongside the application of a drug 
loaded hydrogel patch in order to deliver calcein through excised rat skin utilising a 
similar in vitro Franz diffusion set up as Henry et al. MN arrays manufactured from 
polycarbonate were produced by first creating so called “in-plane” MNs which were 
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then grouped together to create 2D arrays of MNs, or “out-of-plane” MNs of various 
lengths and densities (Figure 1.6).  
 
 
Figure 1.6: Out-of-plane MN array (left) created from grouping several in-plane MNs fabricated from 
polycarbonate. Magnified image of single MN projection from array (right). 
 
The arrays comprised of 200 µm and 500 µm long projections with densities of 45, 
99 and 154 MNs/cm2. The hydrogel patch loaded with 1mM calcein was formulated 
from carbopol 940 and triethanolamine. The investigators determined that the 
delivery rate of the target compound was positively affected by increased MN length 
and density, with the greatest rate of diffusion observed with 500 µm MNs with a 
density of 154 MNs/cm2.  
 
This approach of pre-treating the skin with solid MNs and then placing a drug loaded 
patch over the area has been termed the “poke and patch” method and has been 
successfully demonstrated in human subjects to enhance transdermal delivery of 
hydrophilic drug molecules that would otherwise not permeate through the 
hydrophobic stratum corneum. Wermeling et al.79 carried out a small scale human 
trial (six treated and three control subjects) to demonstrate the delivery of 
Naltrexone, an opioid receptor antagonist for the treatment of opiate and alcohol 
dependence, using the poke and patch method.  
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Arrays consisting of 50 stainless steel MNs (Figure 1.7) were inserted into the skin of 
the subjects across four patch sites for a few seconds before removal. Subsequently, 
adhesive patches containing (% w/w) 16% Naltrexone HCl, sterile water for injection 
(20.25%), propylene glycol (60.75% USP), 2% hydroxyethyl cellulose and 1% benzyl 
alcohol were placed over the application sites for the study duration. Steady state 
plasma concentrations of Naltrexone were detected in the treatment groups after 2 
hours and this was maintained for at least 48 hours, whereas no detectable quantity 
of drug in the plasma was found in the control group that did not have skin pre-
treatment. 
 
Figure 1.7: (A) MN array of 50 stainless steel projections for pre-treatment of skin. (B) Resultant 
micropores created by application of MN array on human volunteers visualised with gentian violet (C) 
Adhesive drug loaded patch for subsequent application to pre-treated skin 
 
1.7.2 Coated MNs 
The poke and patch method of using solid MN arrays to create transient micropores 
in the skin followed by drug application has been shown as a feasible method to 
enhance the transdermal delivery of otherwise skin impermeable hydrophilic drugs. 
However, it is inherently inconvenient for the patient as it requires two distinct steps, 
which could negatively affect patient compliance and increase the risk of improper 
use.   
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Coating MNs with the target drug or material that is to be delivered circumvents the 
need for two steps, as the target compound is delivered to the skin during the MN 
application step. However, due to the small surface area of MN arrays the total 
amount of target compound that can be delivered is dependent on the array size. 
Therefore, the type of payload suitable for coated MN arrays is limited to extremely 
potent materials where the clinically effective dose is extremely low. Suitable 
payloads include vaccines80,81, steroids82, peptides83 and genetic material84,85. 
 
1.7.3 Dissolvable MNs 
MN arrays composed of water soluble polymers have been used as drug delivery 
vehicles via incorporation of the target compound into the polymeric matrix of the 
MN. When the MN is applied, the ISF in the epidermis dissolves the polymer and the 
target compound is released from the MN and into the skin. From there the target 
compound can exert its effect locally or can be absorbed into the blood stream for 
systemic effect. Some example materials include carboxymethylcellulose86,87, 
maltose88, chitosan89 and poly(vinyl alcohol) (PVA)90,91. 
As the objective of these devices is for the polymer matrix to dissolve in the skin, it is 
necessary for the polymer material to be biocompatible. Hyaluronic acid (HA) and 
poly(vinylpyrrolidone) (PVP) which are approved for use by the Food and Drug 
Administration have been used to fabricate dissolvable MNs containing gentamicin92, 
an aminoglycoside typically used to treat severe gram negative  infections93. The MNs 
consisted of a 19 x 19 arrays of needles, 500 µm in height (Figure 1.8) and exhibited 
complete dissolution 5 mins after insertion into neonatal porcine skin. In a murine 
animal model, successful delivery of gentamicin was observed with the maximum 
plasma levels achieved between one and six hours post application.  
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Figure 1.8: (Above) Photograph of dissolvable MN arrays containing gentamicin (Below) OCT images 
of insertion and subsequent dissolution of 19 x 19 MN array in neonatal porcine skin. Reproduced 
from González-Vázquez et al.91 
 
The delivery of insulin has also been investigated using dissolvable MNs94. A 
formulation composed of starch and gelatin was used to encapsulate insulin before 
formation into MN arrays that were robust enough to withstand penetration into 
porcine skin in vitro. The hypoglycaemic effect of the insulin delivered from the MNs 
was observed to be similar to a subcutaneous injection of the insulin in a rat animal 
model.  
 
1.7.4 Hydrogel forming MNs 
Swellable hydrogels can be prepared from polymers that are initially water soluble 
but when crosslinked become water insoluble. Rather than dissolving, the polymer 
will swell with fluid that is drawn into the structure by hydrophilic or ionised groups 
such as hydroxyl (−OH), carboxylic (−COOH), amine (-NH2) and amidic (−CONH-) 
residues present in the polymer chains95. Swellable hydrogels that are used in MN 
manufacture generally consist of a crosslinked polymer network that forms a 
mechanically robust structure when in the dry state (xerogel) which then rapidly 
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imbibes fluid and swells in volume when placed in contact with aqueous solutions. In 
this way, hydrogel MNs can be used to pierce through the outermost layers of the 
skin and swell with ISF. This provides a path for any drugs loaded within the MN to 
diffuse into the skin and exert their effect locally or be delivered systemically.  
For drug delivery purposes a number of different polymers have been used to create 
hydrogel MNs. Arrays consisting of PVA crosslinked by freeze thaw cycles96 has 
successfully demonstrated in vitro delivery of insulin in a Franz diffusion cell 
experiment with porcine skin. Approximately 50% of the insulin loaded into the MNs 
was released over 6 h. The swelling of the MN with ISF can be seen in Figure 1.9 
wherein blank crosslinked PVA hydrogel MNs were inserted into the arms of human 
volunteers for up to 3 hours.  
 
 
Figure 1.9: PVA MN arrays fabricated from crosslinked PVA swelling due to insertion into human skin 
(A) Before insertion (B) 1 h after insertion (C) 3 h after insertion  
 
1.8 Anatomy of the skin 
The skin can be stratified into two layers - the epidermis and the dermis, which are 
delineated by the epidermal-dermal junction. Below the dermis exists a layer of 
subcutaneous fatty tissue known as the panniculus adiposus which is separated from 
the deeper regions of the rest of the body by a layer of striated muscle known as the 
panniculus carnosus. The main anatomical features of the skin are conserved across 
the entire surface of the body however the glabrous skin present on the soles of the 
feet and the palms of the hands has a thicker epidermis, is devoid of hair follicles and 
sebaceous glands and has encapsulated sensory organs in the dermis97. The non-
glabrous skin, or hairy skin, that is present on the rest of the body, is marked by the 
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presence of hair follicles and sebaceous glands. Sweat glands are present on all skin 
surfaces at a density ranging between 100 - 400 glands / cm2.  
1.8.1 Epidermis 
The most superficial skin layer, the epidermis, consists almost entirely of 
keratinocytes which produce numerous fibrous proteins named keratins which add 
mechanical rigidity to the cells as well as long chain saccharides named 
glycosaminoglycans98. Keratinocytes form 95% of the cellular mass of the epidermis 
and originate from the basement membrane at the epidermal-dermal junction. 
Initially keratinocytes are formed attached to the basement membrane, however, as 
they mature they migrate progressively toward the surface of the skin and as such 
the epidermal keratinocytes are grouped into four distinct layers – the stratum 
basale, stratum spinosum, stratum granulosum, stratum lucidum and the stratum 
corneum (Figure 1.10). The layers are differentiated from each other by the 
morphology and function of the keratinocytes which are in different stages of 
maturity.  
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Figure 1.10: Human skin histological image showing layers of epidermis and dermis99 
 
The stratum basale is the deepest later of the epidermis and largely consists of a 
single layer of stem cell keratinocytes at the epidermal-dermal junction100, however, 
it may be two or three cells thick in glabrous or hyperproliferative skin97. Mitosis of 
the keratinocytes in this layer produces daughter cells, of which half migrate toward 
the skin surface and the other half remain at the basement membrane. As the 
keratinocytes move into the stratum spinosum they lose the ability to divide and 
begin to join together through intracellular bridges to form desmosomes that add 
strength and flexibility to the skin101. Cessation of metabolic activity and apoptosis of 
the keratinocytes is observed in the stratum granulosum leading to an almost 
complete keratinisation of the cells102. The stratum corneum is the outermost layer 
of the epidermis and is comprised of dead, flattened keratinocytes that are each 
attached to its neighbour forming a barrier against external stimuli such as chemicals, 
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heat and microorganisms. The entire process of the migration of the keratinocytes 
from the stratum basale to the stratum corneum takes approximately 28 days in a 
0.1 mm epidermis103. The remaining 5% of cells in the epidermis consist of 
melanocytes, Langerhans’ cells and Merkel cells. Melanocytes give the skin its 
pigmentation through the production of melanin. Langerhans’ cells are dendritic 
immune cells that present antigens to naïve T cells in the lymph nodes in order to 
trigger an immune response. They also play a role in hypersensitivity of the skin and 
chronic inflammatory conditions such as eczema and psoriasis104. The function of 
Merkel cells is not universally agreed upon105. Conventionally thought to play a role 
in mechanoreception, as they can be found associated with nerve terminals, more 
recent research has shown that not all Merkel cells are in contact with neurons and 
it has been suggested that they may serve as a diffuse endocrine system throughout 
the skin106.   
1.8.2 Dermis 
The dermis is situated below the epidermis and is mainly composed of 
polysaccharides and proteins. Fibroblasts, mast cells, histiocytes, monocytes and 
macrophages are all present in the dermis107. The proteins within the dermis are 
comprised mainly of collagen and elastin which are produced by the fibroblasts. In 
fact, 70% of the dry weight of dermis is comprised from collagen which increases the 
tensile strength of the skin. Elastin is much more flexible and aids the skin to return 
to its natural shape after stretching. The dermis is classified into two layers: the 
papillary and the reticular layer (Figure 1.11). 
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Figure 1.11: Vasculature organisation of the dermis. Subcutaneous vessels reach into the dermal layer 
to form the deep vascular plexus and superficial vascular plexus108  
 
The papillary layer is closest to the epidermal-dermal junction and contains less 
neurons and capillaries, while the reticular layer is deeper and contains more 
connective tissue and blood capillaries. Larger blood vessels in the subcutaneous fat 
layer below the dermis branch off into the reticular dermis and form a network of 
capillaries known as the deep vascular plexus109 which supplies hair follicles and 
glands. Vessels also connect this network to the superficial vascular plexus which is 
situated closer to the epidermal-dermal junction in the papillary layer.   
1.9 Pain associated with MNs 
One of the major advantages of MNs over conventional drug delivery and fluid 
withdrawal is the lack of pain associated with MN insertion into the skin. There have 
been a number of studies undertaken to investigate the difference in the perceived 
46 
 
pain of MNs compared to hypodermic needles when used in humans. These will now 
be discussed below.  
To compare the pain caused by different intradermal devices, the magnitude of the 
pain or discomfort upon application must be quantified. However, the inherent 
subjectivity of measuring pain levels in a given individual means this can prove 
difficult.  To facilitate this, investigators commonly ask the subjects to rate the 
severity of the pain on a Visual Analogue Scale (VAS) with each end of the scale 
marked with descriptors or a numerals (Figure 1.12). 
 
 
Figure 1.12: VAS scale for quantification of subjective pain experienced by human subjects. 
Reproduced from Melzack et al.110 
 
Originally used to rate a patient’s perceived wellbeing111 VAS has also been adapted 
to score other indications. The subject is usually asked to mark on the scale the 
intensity of the pain experienced and the distance along the scale is determined112 in 
order to provide a quantifiable measurement.  
Kaushik et al.113 conducted a small scale trial on 12 subjects in order to evaluate the 
pain caused by the application of a silicon MN array containing 400 needles that were 
150 µm in length. The needles had an approximately 80 µm wide base and tapered 
to a 1 µm wide tip. As a positive control, a 26 gauge hypodermic needle was inserted 
into the skin to a depth of 2 mm which was controlled via modification of the needle 
cover to expose only 2 mm of the needle. A negative control was also employed for 
comparison which consisted of a smooth silicon wafer with no MN projections.  
The subjects were blinded to the treatment devices and each subject was exposed to 
each treatment four times in a random order. The subjects were asked to rate the 
intensity of the pain on a 100 mm long VAS that included the terminal descriptors 
“No pain” (0) and “Worst Pain” (100). The mean pain score for the MN array was 
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extremely low (0.67) and was not found to be statistically different from the negative 
control (0.42) (p = 0.09), whereas the hypodermic needle was reported to cause the 
most pain (mean pain score = 23.9) which was statistically different to the mean pain 
score of the MN array (p < 0.001). These results demonstrated that this particular 
MN array was indistinguishable from the application of a blank silicon wafer and, 
therefore, could justifiably be described as painless. An important consideration is 
the 150 µm length of the MNs used in this study, which is relatively short in 
comparison to other MNs that have ranged up to 1400 µm in length114.  
The pain associated with MNs of greater length was investigated using a solid MN 
array and hollow MN array in 18 human subjects115 . The solid MNs were composed 
of stainless steel wire that had been cut in order to give it a bevelled edge (Figure 
1.13). 
 
Figure 1.13: (A) 4x4 MN array fabricated from solid stainless steel wires (B) individual MN from solid 
MN array (C) 4x4 MN array fabricated from hypodermic needles (D) individual MN from hollow MN 
array 
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The 4 x 4 arrays were made with MNs of either 200 µm, 300 µm or 400 µm in length 
(200S, 300S and 400S). The 4 x 4 hollow array was fabricated using stainless steel 
hypodermic needles and were either 300 µm or 550 µm in length (300A and 550A). 
The subjects were asked to rate the intensity of the pain immediately after 
application of each MN (Figure 1.14). Blank baseplates were used as negative 
controls.  
 
Figure 1.14: (a) Pain scores for solid MN arrays with increasing MN height (200µm – 400 µm) (b) Pain 
scores for solid MN 300 µm in height compared to hollow MN 300 µm and 550 µm in height. 
 
As Figure 1.14 shows, the average pain scores were quite low, with the median for 
all MNs rated as 1 out of 10 apart from the longest MN of 550 µm, which was 2. There 
was no significant difference found between the negative control compared to any 
other MN array irrespective of the length, diameter or whether it was comprised of 
solid or hollow MNs. This study demonstrated that MNs of a greater length than the 
49 
 
previous investigations by Kaushik et al.113 did not cause any significant pain 
compared to the control. 
In a 12 human subjects trial116 comparing the pain response of a 25 gauge 
hypodermic needle to two solid MN arrays of 180 µm and 280 µm long needles a 
sensory questionnaire was undertaken to describe the types of sensation 
experienced by the subjects (Figure 1.15). 
 
Figure 1.15: Results from sensory questionnaire designed to determine the types of sensation 
experienced from human subjects after application of two types of solid MN arrays (180 µm and 280 
µm in height) compared to a 25 gauge hypodermic needle. White and black sections of each bar 
represent reported mild and moderate sensations respectively. 
 
The subjects commonly chose the descriptors of “Pressing” and “Heavy” in relation 
to the application of the MN arrays whereas the terms “Pricking”, “Sharp” and 
“Stabbing” was chosen more frequently and were more often described as moderate 
in intensity rather than mild for the 25G hypodermic needle. “Sharp” was chosen by 
subjects to describe the MN arrays however this was universally classed as a mild 
intensity unlike the hypodermic needle treatment. Results on  the pain rating  of the 
devices using a 100 mm VAS indicated that both the 180 µm and 280 µm MN arrays 
caused statistically significant less pain that the hypodermic needle (p = 0.027 and p 
= 0.0005 respectively). Interestingly, the VAS score of the shorter MNs was 
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significantly greater than the longer MN array (p < 0.05). The investigators suggested 
that this may have been due to the increased force necessary to penetrate the 
stratum corneum using the shorter MN array and so the pressure felt by the subjects 
was greater upon application of the 180 µm array compared to the 280 µm.   
When discussing the pain associated with MNs used to deliver drug or vaccines 
solution, it is useful to consider the stages of administration. The insertion of the MN 
into the skin may cause pain as the skin barrier is broken, however, the subsequent 
delivery of a liquid into the superficial layers of the skin may also cause separate 
discomfort or pain. Van Damme et. al.117 investigated this concept with the MicronJet 
device, which is a hollow MN designed to replace conventional hypodermic needles 
for the delivery of target compounds and vaccines intradermaly rather than 
intramuscularly. The device consists of four inline silicon MNs 450 µm long (Figure 
1.16). The MN array is attached to a plastic adaptor designed to fit a standard luer-
slip disposable syringe conventionally used to deliver vaccines. 
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In this study, one hundred and eighty subjects were allocated evenly into three 
groups with each group receiving either a 0.1 ml dose of a seasonal influenza vaccine 
using the MicronJet device (ID1), a 0.2 ml dose of the vaccine using the MicronJet 
device (ID2) or a 0.5 ml dose of the vaccine using a conventional hypodermic syringe 
administered intramuscularly (IM). The subjects, who were blinded to the type of 
device that was used, were asked to rate the intensity of the pain upon insertion of 
the MN or hypodermic needle, denoted as the “prick-pain”, and then asked to rate 
Figure 1.16: (Above) Micronjet device for attachment to standard syringe. (Below) SEM images of 
silicon MNs from Micronjet device showing morphology of MN tip and array. 
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the pain associated with the injection of the vaccine solution into the skin, denoted 
as the “administration pain”, on a 100 mm VAS 
The mean VAS score for the prick-pain of the ID1 and ID2 groups were 6.6 and 5.5 
respectively whereas the IM group was 12.8. This was a statistically significant 
difference between the ID1 and ID2 group compared to the IM group (p < 0.001). 
However, the mean VAS scores for the administration pain were greater in the ID1 
and ID 2 group (11.5 and 7.2 respectively) than in the IM group (5.6). There was a 
statistically significant difference between the ID1 and IM group (p = 0.001). This 
study highlighted the difference between pain associated with MN insertion 
compared to the administration of liquid formulations using hollow MNs. While the 
insertion of the MN device into the skin was deemed less painful than the insertion 
of a conventional hypodermic needle, the intradermal delivery of a smaller volume 
of a liquid (0.1 ml and 0.2 ml) was more painful than intramuscular delivery of a 
greater volume (0.5 ml). One limitation of this study was that each subject only 
experienced one of the treatment devices. Due to the inherently subjective nature 
of pain, each subject may have given a different rating to the device compared to 
each other and so a paired statistical analysis where every subject received each of 
the treatments may have strengthened the investigation into the pain response. 
However, this may not have been feasible as the efficacy of the influenza vaccine 
administered to each subject was also studied and, therefore, additional treatments 
could not be given to each patient. To overcome this, the additional treatments could 
have contained blank solutions with no vaccine material. 
MNs as long as 2 mm have been investigated for the withdrawal of blood118. A single 
hollow MN fabricated from of silicon was used to withdraw whole blood from 62 
subjects in order to compare its blood glucose measurement accuracy and associated 
pain compared to the standard practice of using a lancet needle and electronic 
handheld glucometer119. The tapered MN was 2 mm in length and 100 µm wide at 
the base and was fabricated with a hollow channel 25 µm in diameter that ran from 
the tip of the MN into the 5 mm2 silicon cuvette housing (Figure 1.17). It was designed 
to allow the passage of the blood from the capillaries near the surface of the skin 
through the MN via capillary action and into the silicon cuvette where the 
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concentration of glucose within the blood sample could be determined using optical 
or electrochemical means.  
 
 
In order to compare the pain associated with the insertion of the single MN device 
to the standard finger prick method, each of the 62 subjects (41 diabetics and 21 non-
diabetics) were exposed to three treatments. The first was using a standard lancet to 
pierce the fingertip to obtain a small volume of capillary blood. The second was the 
administration of the lancet into the arm of the subject and the third was the 
administration of the silicon MN device into the arm. Each subject was asked to rate 
the pain associated with each treatment from 1 – 5 with the following descriptors: 1 
– Barely noticeable, 2 – Slightly painful, 3 – Somewhat painful, 4 – Painful, 5 – Very 
painful. As a significant number of subjects (15%) reported not feeling the silicon MN 
inserting into the skin at all, a rating of 0.5 – ‘Could not feel insertion’, was added to 
the scoring system in order to reflect this.  
Figure 1.17: (Left) Diagram of single silicon MN with cuvette for blood collection and glass window to 
view sample. (Right) SEM image of MN tip with opening for fluid withdrawal 
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Figure 1.18: Pain scores after insertion of ametal lancet needle in finger and arm compared to hollow 
silicon MN in arm. 
 
As can be seen in Figure 1.18, the treatment with the highest mean pain rating was 
the lancet applied to the fingertip (2.3), followed by the lancet applied to the arm 
(1.7) and the least painful was the MN device applied to the arm (1.2). Looking at the 
individual data (Figure 1.19), it was observed that 58% of the subjects responded that 
the silicon MN was barely noticeable whereas less subjects gave this response for the 
lancet in the arm (45%) and even less for the lancet in the fingertip (27%). In fact, 
15% of the subjects responded that they did not notice insertion of the single MN 
into the arm at all.  
55 
 
 
Figure 1.19: Individual break down of pain perception of lancet needle in finger and arm compared to 
hollow silicon MN in arm 
 
1.10 Glucose Responsive MNs for delivery 
Hu et al.120 aimed to produce a detection-delivery system comprising a glucose 
responsive MN that modulated the release of insulin in a so called “closed-loop” 
system. This closed loop system of insulin delivery typically involved glucose 
monitoring coupled to deliver adequate quantities of insulin in order to maintain 
proper glucose levels over prolonged periods without causing hypoglycaemia though 
insulin overdose. Hu et al. incorporated H2O2 sensitive polymersomes containing GOx 
and insulin into the tips of a MN array composed of crosslinked HA. The 
polymersomes were formed from a block copolymer incorporating polyethylene 
glycol (PEG) and a phenylboronic ester-conjugated polyserine which was designed to 
degrade in response to increased concentrations of H2O2 caused by the oxidation of 
glucose by GOx contained within the polymersome. Therefore, in hyperglycaemic 
conditions, the glucose was oxidised to produce increased levels of H2O2 which 
caused the disassembly of the polymersome. This enabled the release of insulin and 
subsequent delivery into the skin to ultimately return the body to normal glycaemia.  
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When administered to streptozocin-induced type 1 diabetic mice the MNs containing 
the GOx and insulin loaded polymersomes (MN[PV(E+I)]) reduced the blood 
concentration of glucose to approximately 90mg/dL (5.0 mM) after 1hr and 
maintained this normal glycaemia for 5 hours compared to blank MNs (MN[HA]) 
which had no significant effect (Figure 1.20).  
 
 
In contrast, MNs loaded with the equivalent amount of insulin (MN[I]) had a 
significantly reduced glucose lowering effect, achieving a blood concentration of 
approximately 400 – 500 mg/dL (22 – 27 mM).  While MNs loaded with 
polymersomes containing insulin only (MN[PV(I)]) had a comparable glucose 
lowering effect to the dual loaded polymersome containing MNs,   the effect was 
significantly shorter lived (2 hours).   When diabetic mice were treated with the MN 
arrays and subsequently challenged with an intraperitoneal (IP) injection of glucose, 
the MN array containing GOx / insulin had a superior glucose lowering effect 
compared to the MN array containing insulin only, and more closely resembled the 
Figure 1.20: (Left) Schematic of HA MN array loaded with H2O2 responsive liposomes containing insulin. 
(Top right) Blood glucose lowering effect of HA MNs loaded with H2O2 responsive polymersomes 
containing insulin (MN[PV(E+I)] compared to blank MNs (MN[HA]), insulin loaded MNs (MN[I]) and MNs 
with insulin loaded polymersomes (MN[PV(I)]) in diabetic mice. (Bottom right) Blood glucose level in 
diabetes mice wearing MN[I] or MN[PV(E+I)]) patches challenged with IP glucose injection compared to 
healthy mice. 
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response to glucose in healthy mice (Figure 1.20) However, it was observed the blood 
glucose was still greater than the healthy mice over the time period of the study (160 
min).  
A further development by the same research group incorporated a hypoxia sensitive 
nitroimidazole group via a H2O2 sensitive thioether linkage in the same PEG / 
poly(serine) co-polymer matrix used to formulate the previous MNs121. Due to the 
consumption of oxygen by GOx mediated oxidation of glucose, hypoxic conditions 
are generated in the local microenvironment. This triggered the conversion of 2-
nitrimidazole within the polymersomes to 2-aminoimidazole via native 
nitroreductases, which is more hydrophilic thus promoting polymersome 
disassembly and insulin release (Figure 1.21). Furthermore, the production of H2O2 
from the oxidation of glucose triggered a second mechanism of polymersome 
disassembly as the thioether moiety of the copolymer reacts with the H2O2 to form 
water soluble sulfone groups. In this way, high glucose concentrations within the ISF 
triggered the release of insulin from the polymersome loaded MNs. The in vivo 
efficacy of the MNs was demonstrated as before in diabetic mice, where the 
administration of MNs containing the dual sensitive polymersome was decreased the 
blood glucose concentration after 1 hour and maintained normal glycaemia for 
approximately 6 hours (Figure 1.21), which was a superior duration of action than 
Figure 1.21: (Left) Blood glucose levels in diabetic mice after application of MNs loaded with dual 
responsive polymersomes containing insulin and enzyme (d-GRP(E+I)) or MNs loaded with d-GRPs 
containing insulin (d-GRP(I)) compared to PBS control or SC injection of insulin (Right) Effect on blood 
glucose due to second treatment after initial application of MN containing d-GRP(E+I). The second 
treatment consisted of either MN containing d-GRP(I), a second MN containing d-GRP(E+I) or a  SC 
insulin. 
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the equivalent dose of free insulin. Moreover, in a separate experiment, application 
of a second polymersome loaded MN 3 hours after an initial MN was applied, did not 
cause hypoglycaemia to occur in diabetic mice, whereas an injection with the 
equivalent dose of free insulin caused rapid hypoglycaemia.   
More recently, MNs based on crosslinked PVA have been reported to provide glucose 
responsive delivery of insulin to diabetic mice122. The MNs consisted of a crosslinked 
PVA gel core embedded with GOx and insulin coated with a PVA shell containing 
catalase. The PVA core was gelated with a H2O2 labile crosslinker based on 
phenylboronic acid thus providing a mechanism of gel degradation in hyperglycaemia 
as before. Similarly, the insulin contained within the core was covalently attached to 
the PVA backbone with the same H2O2 labile thioether linker therefore enabling 
elective insulin release in hyperglycaemia. The purpose of the catalase embedded 
shell of each MN was to provide a H2O2 scavenging layer in order to reduce local 
inflammation to the skin123. Diabetic murine experiments with the MNs showed their 
capability to decrease blood glucose to normal levels and maintain normal glycaemia 
for several hours without causing hypoglycaemia even after repeated application.  
Xu et al.124 have also utilised a H2O2 sensitive mechanism to modulate the release of 
insulin from mesoporous silica nanoparticles loaded into PVP MNs. GOx contained in 
the silica nanoparticles generated H2O2 that hydrolysed phenylboronic esters present 
in the structure, causing nanoparticle degradation and subsequent release of insulin 
that was stored in the nanopores of the silica nanoparticles. In vivo efficacy studies 
in diabetic mice showed a successful hypoglycaemic effect of the MNs due to insulin 
release and the MNs were able to maintain normal glycaemia in the mice for 4.5 
hours compared to 2 hours for a subcutaneous injection of insulin.  
 
1.11 MNs for single measurements of ISF glucose 
An array of hollow MNs was produced from monocrystalline silicon by Mukerjee et 
al.125 that demonstrated successful ISF withdrawal from a human subject with a 
subsequent detection of the ISF glucose demonstrated.  
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The sole driving force behind the ISF extraction was capillary action through the 20 x 
20 array of “snake fang” designed MNs that ranged from 250 – 350 µm in length with 
300 µm centre-to-centre interspacing (Figure 1.22). Upon application, the MN array 
remained embedded in the skin due to the friction between the MN projections and 
the upper layers of the epidermis. Initial in vitro experiments using a wide range of 
liquids such as glycerol, acetone and distilled water showed successful transport of 
liquid from the MN tips through capillary channels that were etched into device to a 
fluid reservoir.  
 
When applied to a human subject’s skin, ISF was observed to travel from the MN 
array through the capillaries and into the reservoir after 15 – 20 minutes. The fluid 
was confirmed as ISF through examination using light microscopy which confirmed 
there was no visible cellular material as would be in whole blood. Additionally, a small 
section of a colorimetric glucose test strip was placed in contact with the fluid after 
extraction (Figure 1.23).  
 
 
Figure 1.22: (Left) SEM image of hollow silicon MN array with “snake fang” design. (Right) Application 
of hollow silicon MN array to finger. 
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A blue colour change was observed after the test period which confirmed the 
presence of glucose in the ISF at an approximate concentration of 80 - 120 mg / dL 
(4.4 – 6.7 mM). Application of a solid MN array followed by collection of ISF using a 
hydrogel patch was used to monitor post-prandial glucose in human subjects within 
the ISF in order to compare against plasma glucose126. The polycarbonate MN 
consisted of a 305 array of 300 µm long MNs and was applied to a total of 47 subjects 
using a spring-loaded applicator with a speed of approximately 6 m/s. Of the 47 
subjects tested, 37 were diabetic and 10 were non-diabetic. After MN application at 
two sites on each subject, a hydrogel patch composed of PVA was placed over the 
pre-treated area and left in place for 2 hours before subsequent analysis of the 
glucose using a commercial fluorescent based assay. From plasma glucose 
measurement taken throughout the study, the area under the curve (AUC) of glucose 
predicted from the ISF was shown to correlate well to the plasma glucose AUC (R = 
0.93). However, the rapid variation in plasma glucose could not be predicted by the 
ISF due to a lag time between the changes in the plasma compared to the ISF.  
Hydrogel forming MNs demonstrated successful extraction of ISF by Caffarel-
Salvador et al.127. Using optical coherence tomography (OCT), it was confirmed that 
the hydrogel MNs became swollen with ISF after insertion into both rats and human 
volunteers (Figure 1.24). In this way, it was proposed that the analytes contained 
within the ISF in the MNs could be measured to provide a minimally invasive and 
blood free mechanism of therapeutic drug and glucose monitoring. 
Figure 1.23: Photograph of segment of glucose test strip placed in ISF collection 
reservoir of hollow silicon MN array. (Left) Before extraction of ISF. (Right) After 
extraction of ISF 
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Figure 1.24: Swollen PMVE/MAH hydrogel MN after 1 h application to (A) back of rat (B) human 
volunteer’s forearm. OCT images of PMVE/MA hydrogel MN in forearm of human volunteer (C) upon 
application (D) 1 h after application. 
 
The MNs, composed of hydrolysed PMVE/MAH (11.1% w/w) crosslinked with PEG 
(5.6% w/w) were first applied to neonatal porcine skin in a Franz diffusion cell set-up 
that had been bathed on the underside with phosphate buffered saline (PBS) 
containing various concentrations of either caffeine, theophylline or glucose. For 
glucose, test solutions of 4.0 mM and 15.0 mM glucose were used, possibly to 
represent normal glycaemia and hyperglycaemia respectively. 5 mins and 60 mins 
post application, the glucose within the MNs was quantified using a proprietary kit 
after allowing the analytes contained within each MN to diffuse from the hydrogel 
into a volume of distilled water. After only 5 mins there was a detectable quantity of 
glucose within both MN arrays with a concentration of 19.46 nM in the 4.0 mM 
group, however there was no significant difference in the concentration measured in 
62 
 
the MNs exposed to the 15 mM glucose compared to MNs exposed to 4.0 mM 
glucose at either 5 mins or 60 mins post application.  
In order to investigate the ability of the hydrogel MN to track changes in the ISF over 
time, MNs were also applied to human volunteers after ingestion of 75g of glucose 
powder. The concentration of glucose in the MNs was compared to plasma blood 
glucose determined using an electronic glucometer from fingertip blood samples. 
MNs were applied for one hour before the ingestion of the glucose (-1 – 0 h), for the 
first hour post ingestion (0 – 1 h), the second hour (1 – 2 h), the third hour (2 – 3 h) 
and for the entire three hours after ingestion (0 – 3h) (Figure 1.25). 
 
Figure 1.25: Concentrations of glucose measured in PMVE/MAH hydrogel MNs applied to human 
volunteers to measure ISF glucose compared to blood glucose measurements after ingestion of 75g 
of glucose at 0h time point. 
 
While the concentrations within the MN were all significantly different than the 
plasma blood glucose concentrations, it was confirmed that they were capable of 
extracting ISF from the skin and the glucose could be quantified. The peak plasma 
glucose was observed 1 hour after ingestion of the glucose powder, with the peak ISF 
concentration 3 hours post ingestion. This demonstrated a lag time between changes 
in the plasma glucose and changes to the ISF glucose concentration of approximately 
2 hours. This lag time has been observed in previous studies126.  
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An alternative approach for the collection of analytes from hydrogel forming MNs 
was suggested by Romanyuk et al. to enable a higher throughput of samples128. 
Loading a model analyte, sulforhodamine into the tips of MN arrays composed of 
PMVE/MA (15% w/w) crosslinked with PEG (7.5% w/w), various methods of analyte 
recovery were investigated. Through attachment of the preloaded MN arrays to the 
underside of the lids of microtubes designed for centrifugation, the investigators 
added 100 µL of distilled water to each MN and incubated for 1, 5 and 10 mins 
followed by centrifugation for 20 s at 300G. After one centrifugation cycle, the 
fraction of analyte recovered was found to be dependent on the incubation time, i.e. 
more analyte was recovered after longer incubation periods, and 100% of the analyte 
was recovered after three successive cycles of centrifugation, independent of 
incubation time (Figure 1.26). A second method of analyte recovery more suited to 
high throughput of samples and subsequent analysis involved the use of microplates. 
The MNs were each fixed to a hard plastic backing material and placed on to the open 
top of microplates so as to act as lids for each well. The MNs were situated on the 
underside of plastic lids so they protruded into each well, which was filled with an 
aliquot of distilled water. The plates were then inverted in order to move the water 
into contact with each MN to allow the recovery of the model analytes into the 
distilled water. After incubation, the plates were returned to the original orientation 
and the MNs were removed. In this way, a large number of MNs could be processed 
simultaneously and the analyte solution could be further analysed in the microplate 
through enzymatic, UV/Vis or fluorescent assays as required.  
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Figure 1.26: Percentage recovery of model analyte from PMVE/MAH hydrogel MNs utilising successive 
centrifugation cycles after 1 min, 5 min or 10 min elution times. 
 
Another polymer used to produce hydrogel forming MNs is crosslinked HA129 due to 
its excellent swelling capability and biocompatibility. In order to form a swellable 
hydrogel from water soluble HA, the structure was chemically modified through 
functionalisation with methacrylate groups130, which can undergo facile 
polymerisation to form covalent crosslinks between the polymer chains. This enabled 
the polymer to swell and absorb large quantities of water instead of dissolving. 
Polymerisation was achieved through free radical catalysis with a photoinitiator 
activated with UV light.  The degree of crosslinking enabled control of the swelling 
capability of the MNs prepared from this crosslinked HA, with MNs irradiated for 
longer periods becoming more densely crosslinked and thus capable of absorbing 
less water from agarose gel, which was used as a tissue surrogate (Figure 1.27). 
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Figure 1.27: Swelling ratio of crosslinked HA MNs applied to agarose gels. MNs were crosslinked for 
either 3 mins (HAMA-MN-CL3), 5 mins (HAMA-MN-CL5), 10 mins (HAMA-MN-CL10) or 15 mins 
(HAMA-MN-CL15). 
 
After successful extraction and recovery of the model compounds rhodamine B, 
glucose and cholesterol from the agarose gel tissue surrogate, the investigators 
evaluated the effectiveness of the MNs in a mouse model.  Four 10 x 10 arrays with 
a MN height of 800 µm were pressed into the skin on the back of mice with thumb 
pressure. After 1 min, the total ISF extracted by MNs was measured to be 1.4 ± 0.3 
mg. After 10 min, the mass of ISF was 2.3 ± 0.4 mg. This was substantially greater 
than the amount of ISF extracted in 1 hour reported by Romanyuk et. al.128 using 
PMVE/MA (15.0%) and PEG (7.5%) MN arrays. The mice were administered an IP 
injection of glucose after 1 hour followed by an IP injection of insulin 1 hour later. 
MNs were applied 30 mins after each injection in order to determine if the change in 
glucose in the blood stream was observed in the ISF. In order to observe a change in 
the cholesterol, mice were fed on a high fat diet for up to three weeks prior to the 
experiment. After each 10 mins application the MNs were removed and the quantity 
of glucose and cholesterol were determined using a commercial glucose assay and 
cholesterol quantification kit respectively (Figure 1.28).  
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Figure 1.28: (Left) ISF and blood glucose concentration measured by application of crosslinked HA MN 
or blood glucose meter respectively in mice which were administered IP glucose followed 1 h later by 
IP insulin. (Right) ISF cholesterol and blood cholesterol measured by crosslinked HA MN or blood 
cholesterol meter respectively over 21 days of a high fat diet in order to increase cholesterol levels. 
 
It was demonstrated that the crosslinked HA MNs were capable of providing a 
minimally invasive method to determine the concentration of glucose and 
cholesterol in the mice with good correlations between ISF glucose concentrations 
and plasma glucose measured. The ISF cholesterol was consistently lower than the 
plasma cholesterol and, therefore, the investigators suggested that calibration would 
be necessary in order to indirectly determine the plasma cholesterol from ISF 
measurements.  
 
1.12 Flash glucose monitoring device  
The Freestyle Libre is a flash glucose monitor that can provide a measurement of the 
glucose concentration in the ISF present in the dermal layer of the skin131. The sensor 
of the device is a filament that penetrates the epidermis skin layer and becomes 
embedded in the dermal layer to a depth of 5 mm (Figure 1.29). At this depth, the 
ISF is in equilibrium with the glucose present in the plasma with a lag time of 
approximately 5 minutes.  Each sensor module can remain embedded in the skin for 
14 days before being removed and replaced by a new unit. To display the ISF glucose 
concentration, a companion device or smart phone can be used to wirelessly transfer 
the data stored within the sensor unit to display to the user.  
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Figure 1.29: Schematic of Freestyle Libre sensor device embedded in skin to provide flash glucose 
measurements over 14 days131 
 
The largest trial of the Freestyle Libre device to date is the IMPACT study132 which 
included 242 participants with Type 1 diabetes. The aim of the multicentre, 
prospective, non-masked trial was to compare the rate of hypoglycaemic events in 
120 participants using the Freestyle Libre to 121 participants that used conventional 
SMBG techniques over 6 months. A 30% or greater reduction in hypoglycaemia was 
predetermined as clinically relevant by the American Diabetes Association133. The 
mean time spent in hypoglycaemia for the Freestyle group decreased from 3.38 
h/day to 2.03 h/day whereas the control group decreased from 3.44 h/day to 3.27 
h/day after 6 months. Adjusting for the small decrease observed in the control group, 
the mean time in hypoglycaemia for the Freestyle Libre group reduced by 38% and 
so was deemed clinically relevant. There were four allergy related adverse events 
and four severe insertion site symptoms. Other adverse events were mild or 
moderate erythema or oedema.  
Another trial investigated the accuracy of the ISF glucose measurements to the blood 
glucose measurements obtained in 72 participants with either Type 1 or Type 2 
diabetes over 14 days134. The sensor was initially factory calibrated and not further 
calibrated with blood glucose measurements throughout the trial. Comparison 
between approximately 8 daily blood glucose readings to ISF glucose revealed a 
mean absolute difference of 11.4% and a mean lag time of 4.5 - 4.8 mins. On days 2, 
7 and 14 the percentage of readings within the Consensus Error Grid Zone A was 
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88.4%, 89.2%, and 85.2% respectively, with 99.7% of reading within Zone A and B 
(Figure 1.30). As of November 2017 the Freestyle Libre is available on the NHS after 
initiation under diabetic specialist teams135.  
 
Figure 1.30: Consensus Analysis of Freestyle Libre ISF glucose readings and blood glucose readings 
with in-built glucose monitor over 14 days continuous use134. 
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1.13 Aims and Objectives 
The main aim of the work carried out in this thesis was to investigate the feasibility 
of a MN based approach to measure ISF glucose concentration. The specific 
objectives were: 
1. To determine the most effective MN for the rapid extraction of glucose 
solution. 
2. To develop and optimise an optical detection system for glucose that would 
provide a colorimetric response to glucose concentration. 
3. To identify a suitable housing for the optical detection system that permits 
integration with the MN baseplate.  
4. To test the feasibility of the resulting MN-sensor constructs for their ability to 
extract and determine glucose concentrations from the colour change in a 
timely manner. 
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Chapter 2 
2.0 Materials and Methods 
2.1 General 
2.1.1 Materials, Equipment and Reagents 
All chemicals were purchased from Sigma-Aldrich (Gillingham, UK) and used without 
further purification unless otherwise indicated. Solvents were also purchased from 
Sigma-Aldrich (Gillingham, UK). Poly(dimethylsiloxane) (PDMS) MN templates were 
purchased from Micropoint Technologies Pte Ltd. (Singapore). Custom centrifuge 
inserts to house the MN templates were fabricated from polypropylene. A Form 1+ 
SLA printer (Formlabs, MA USA) was used to print all CAD schematics using Formlabs’ 
proprietary clear resin. For all digital photography a Canon EOS 100D DLSR camera 
(Canon Digital, Tokyo, Japan) was used with a Canon EFS 18 - 55mm lens. The 
following settings were used in manual mode - shutter speed: 1/30, aperture f/5.6 
and ISO 400. An intervalometer was used with the camera for repeated photography 
at set time points. For axial load tests a single column load tester Instron® 3344 
(Buckinghamshire, UK) was utilised. A Varian Cary UV-Vis spectrophotometer was 
used to obtain al UV-Vis spectroscopy data with a 10 mm pathlength quartz cuvette. 
UV irradiation of polymer solution was carried out using a UVGL-58 handheld UV 
lamp (UVP, Cambridge, UK). pH measurements were obtained using an electronic pH 
meter (Hanna Instruments). Hydrochloric acid and sodium hydroxide solutions were 
used to lower and increase pH respectively. 
2.2 Polymeric Hydrogel Microneedles for the Extraction and Optical Detection of 
Glucose 
2.2.1 Swelling studies of PMVE/MA hydrogels crosslinked with PEG 
Pre-gel co-polymer blends were prepared consisting of PMVE/MA (20% w/w), PEG 
(MW 10,000 Da) (7.5% w/w) and increasing quantities of sodium carbonate (0-5%). 
PMVE/MA was added to distilled water and heated at 90°C for 1 h until fully 
dissolved. After cooling to 25oC, PEG and sodium carbonate were added and the 
solution stirred to obtain a homogenous pre-gel blend. To remove air bubbles, the 
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pre-gel blend was centrifuged at 1000 x g for 15 mins and then poured into square 
13 mm x 13 mm silicon moulds. The gels were dried at ambient temperature for 48 
h, removed from the moulds and cured at 80°C for 24 h to induce chemical 
crosslinking by esterification. To determine the swelling capability, each gel square 
was submerged in PBS (20 mL) at 25oC. The gel was removed after 0.5 h, 1 h, 2 h and 
5 h, surface dried using filter paper and weighed. A plot of percentage swelling over 
time was generated for each formulation (Figure 3.3). 
2.2.2 Manufacture of MNs prepared using polymer 2 
Polymer 2, consisting of PMVE/MA (20% w/w), PEG (MW 10,000 Da) (7.5% w/w) and 
sodium carbonate (3% w/w) was used to prepare MNs. The pre-gel blend was 
prepared as discussed in Section 2.2.1. This was then poured into silicon MN 
templates (Micropoint Technologies, Singapore) so as to exclude air bubble 
formation. The templates were centrifuged in a custom holder at 800 x g for 20 mins 
and allowed to dry at ambient temperature for 48 h. The MNs were removed from 
the templates and placed in an oven at 80°C for 24 hours to induce chemical 
crosslinking by esterification and yield hydrogel MNs. 
Double filled MNs were produced by filling templates with 60 mg of polymer 2 before 
centrifugation at 800 x g for 20 mins. The templates were allowed to dry at room 
temperature for 24 h. A second addition of polymer 2 was added to each mould using 
a pipette until each mould was slightly overfilled. They were allowed to dry for a 
further 24 h at room temperature followed by heating in an oven at 80°C. The MNs 
were then removed from the moulds and the excess dried polymer was trimmed 
using a scalpel to yield MNs with a smooth backplate. Ten of the single and double 
filled MNs were weighed in order to determine the uniformity of weight using each 
method.  
2.2.3 Development of the glucose sensor 
For all photophysical experiments, stock solutions of 3,3',5,5'-Tetramethylbenzidine 
(TMB) in ethanol and D-Glucose in de-ionised water were prepared. The aqueous 
glucose stock was allowed to mutarotate for at least 2 h. Unless otherwise specified, 
for UV/Vis studies a solution of GOx/HRP (425 units/L) and TMB (42 µM) in sodium 
acetate buffer (pH 5.4) was used as the enzyme-dye system. Each 1 ml aliquot of the 
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enzyme-dye system was spiked with an aqueous glucose solution in order to give a 
final concentration of 200 µM glucose. The absorbance spectra between 200 nm – 
800 nm were recorded at 60 s intervals over the course of 15 min (Figure 3.10) 
To investigate how to modify the rate of blue charge transfer complex formation in 
Figure 3.12, four different solutions were prepared with a final concentration of 
either 850 U/L GOx/HRP and 84 µM TMB, 850 U/L GOx/HRP and 42 µM TMB, 425 U/L 
GOx/HRP and 84 µM TMB or 425 U/L GOx/HRP and 42 µM TMB in sodium acetate 
buffer (pH 5.4). Each solution was spiked to contain a final concertation of 200 µM 
glucose. The UV/Vis absorbance at 650 nm was measured at 60 s intervals for 15 
mins.  
In order to test the response to a range of glucose concentrations (Figure 3.13), eight 
solutions containing the enzyme-dye system (GOx/HRP (425 units/L) TMB (42 µM)) 
were spiked with aqueous glucose solutions in order to contain a final concentration 
of either 0 µM, 10 µM, 50 µM, 100 µM, 150 µM, 200 µM, 300 µM, 500 µM, 750 µM 
or 1000 µM glucose. The absorbance spectrum for each was recorded after 8 mins. 
To increase the linear range of the sensor, solutions containing 42 µM TMB in sodium 
acetate buffer (pH 5.4) and either 425 U/L, 212 U/L or 106 U/L GOx/HRP were spiked 
with glucose in order to obtain final concentrations of 0 µM, 10 µM, 50 µM, 100 µM, 
150 µM, 200 µM, 300 µM, 500 µM, 750 µM or 1000 µM glucose. The absorbance of 
each solution at 650 nm was recorded after 8 mins (Figure 3.16). 
2.2.4 Investigation of glucose sensor performance of polymer 2  
Pre-gel blends of polymer 2 were prepared as described in Section 2.2.1. Before 
casting into moulds, a 1 ml aliquot of the polymer 2 pre gel blend was pipetted on to 
a weigh boat and photographed 5 mins and 10 mins after addition of a 10 mM 
glucose solution (100 µL) (Figure 3.17). 
A MN composed of polymer 2 prepared using the method detailed in Section 2.2.2 
was submerged in a 3 mL solution containing 425 U/L GOx/HRP and 42 µM TMB in 
sodium acetate buffer. After 2 h the MN had imbibed the solution and any surface 
solution removed with filter paper. A 100 µL aliquot of 10 mM glucose solution was 
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pipetted on to the surface of the swollen MN and imaged after 4 and 8 mins (Figure 
3.17). 
2.2.5 Synthesis of PMVE/MA and TPME backplates 
PVME/MA (2g) was dissolved in distilled water and heated to 90°C for 1h. Upon 
cooling, tri(propyleneglycol) monomethyl ether TPME (1g) was added and the pH 
adjusted to 5.4 with 3 M NaOH. The final weight of the solution was then made up to 
10 g with distilled water. GOx/HRP and TMB solutions were added to the gel to obtain 
final concentrations of 425 U/L and 42 µM respectively. To remove air bubbles the 
pre-gel blend was centrifuged at 1000 x g for 15 mins and then poured into square 
silicon moulds with 10 mm x 10 mm dimensions. The gel was allowed to set overnight 
in a fume hood at 25 °C. For attachment to hydrogel MNs, a small quantity of distilled 
water (1 µL) was added to the centre of the backplate before placing on to the back 
of the MN and dried at 25 °C in a fume hood. 
2.2.6 In vitro extraction of glucose from simulated ISF 
MNs were fabricated from polymer 2 as detailed in Section 2.2.2 and interfaced with 
sensor embedded TPME backplates as described in Section 2.2.5. The MN 
projections were penetrated through a single layer of Parafilm using thumb pressure 
and placed on the surface of glucose solutions (0 – 10 mM) (PBS) to start the 
extraction procedure. Photographs of the backplates were taken over 1 h (Figure 
3.21). 
2.2.7 Fabrication of sensor embedded paper backplates 
Whatman No 1 paper was used to create square backplates measuring 10 mm x 10 
mm. Each backplate was submerged in 3.5 mL of a 50:50 distilled water : ethanol 
solution containing GOx/HRP and TMB for 5 min. In order to optimise the quantities 
of GOx/HRP and TMB, four formulations (A-D) contained different amount of enzyme 
but the same quantity of TMB were prepared. The quantities for Formulation A-D are 
listed in Table 3.1. The backplates were then removed and allowed to dry at 25 °C for 
2 h. 
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2.3 Single Hollow Microneedle Device for the Extraction and Colorimetric Detection of 
Glucose 
2.3.1 3D printing of solid MNs and MN master moulds using Form 1+ printer 
CAD schematics of MNs for 3D printing were initially created using SketchUp 
(Trimble) in order to produce STL (stereolithography) files that are native to 3D 
printing software and were suitable for the Form 1+ printer. In order to repair any 
issues with the CAD schematics before printing, the files were analysed using 
NetFabb basic (Autodesk) and default repairs were carried out if necessary.  
The Form 1+ printer resolution was set to 0.025 mm. After STL files were loaded into 
the Formlabs printer software, default supports were added to the models and 
modified if necessary to avoid creating points of contact between the key areas of 
the model and the support (e.g. MN tips or inner areas of moulds). After printing, 
models were removed from supports using cutting pliers and washed twice in 
isopropanol and dried in an oven at 50 °C for 1 h.  
2.3.2 Production of negative silicone moulds for hollow MN 
A 30G needle was inserted into the 3D printed mould until the tip came into contact 
with the attached lid. The lid was removed and the needle was fixed in place with 
cyanoacrylate glue. Room temperature vulcanising (RTV) silicone (Viscolo 13, TOMPS 
UK) was used to create a negative mould of the master mould with the attached 
needle (Figure 2.1). The silicon was prepared according to the manufacturer’s 
instructions. Equal amounts by volume of part A and B were thoroughly mixed in a 
50 ml polypropylene tube using a stirring rod. The bubbles introduced from the 
mixing were removed by placing the open tube in an upright position in a vacuum 
oven at RT. A vacuum was applied to the oven for 30 mins until no visible bubbles 
remained. The silicone was then taken up into a 5 ml syringe which was subsequently 
attached to the needle hub in the 3D printed mould. The silicone was pushed through 
the needle until a small quantity of the liquid exuded from the tip. The syringe was 
then removed and the mould was placed on an even surface. The remaining silicone 
from the 50 ml centrifuge tube was then poured into the mould until it was 
completely filled, avoiding the introduction of air bubbles. The silicone was left to 
crosslink for 16 h at 25°C. After fully solidifying, the silicone negative mould was 
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peeled away from the 3D printed master mould, ensuring the thin line of silicone that 
protruded into the barrel of the needle remained attached to the base of the 
negative mould. The mould was washed with distilled water and then methanol 
before being allowed to dry at 40 °C for 60 mins. 
 
Figure 2.1 Fabrication of silicone negative mould for production of hollow polymer MN 
 
2.3.3 Single hollow polymer MN  
A stock solution containing glycidyl methacrylate (GMA) (10 ml), trimethylolpropane 
trimethacrylate (TRIM) (5.23 ml), triethylene glycol dimethacrylate (TEGDMA) (15.7 
ml) and Irgacure 184 (0.1 g) was prepared. If not used immediately, the solution was 
wrapped in aluminium foil to avoid inadvertent polymerisation from ambient light 
and refrigerated at 5 °C overnight. An aliquot of 150 µL of the solution was added to 
each of the negative silicone moulds while the length of silicone that replicated the 
inner bore of the needle was held upright at 90°C using a small scaffold structure. To 
ensure the moulds were completely filled, they were placed in a vacuum oven at RT 
and a vacuum was applied for 60 mins to force the liquid into the tip of the moulds. 
The monomer mix was then polymerised using a 365nm emitting UV lamp (6W, 50Hz, 
0.12 A) for 30 mins until the polymer mix had fully solidified. The hollow MNs were 
then removed from each mould and washed with methanol before drying in an oven 
at 40 °C for 60 mins.  
2.3.4 Kinetics of Methylene Blue extraction using the hollow MN device. 
An aqueous solution (30 mL) of methylene blue (MB) at a concentration of 1.0 mM 
was added to a plastic 90 mm petri dish. A hollow polymer MN was pierced through 
a single layer of Parafilm to simulate skin penetration. Segments of Whatman No. 1 
filter paper were cut into 5 mm2 squares and attached to the back each MN device. 
The MNs were then placed on the surface of the MB solution ad photographs of the 
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paper square backplate were taken at 1 s intervals for 5 s in order to capture the 
extraction of the coloured solution (Figure 4.8).   
2.3.5 Mechanical testing of the hollow MN device 
The magnitude of the force required to fracture the single MN in the hollow polymer 
MNs was measured using an axial load test station with a 50 N load cell. The MNs 
were fixed to a horizontal metal block using double sided adhesive tape. To enable 
sufficient adhesion to the tape and to avoid any lateral movement during axial 
compression, the backplate of each MN was first roughened using sandpaper before 
application of the adhesive tape. A metal rod with a diameter of 4 mm was driven 
downwards on to the MN tip at a rate of 0.01 mm/s until fracture of the MN occurred. 
This was monitored using an optical microscope to visually confirm that the rod was 
lowered directly on to the MN tip and that breakage occurred. 
2.3.6 Measurement of ChromB in MB soaked paper backplates 
Stock solutions of MB (0-1 mM) in distilled water were prepared. Blank paper 
backplates were submerged in each solution, removed and allowed to dry at room 
temperature. Photographs of each backplate were recorded and the ChromB values 
calculated. This was achieved by obtaining the red (R), green (G) and blue (B) values 
from the photograph of the backplate using ImageJ with the RGB measure plugin. 
The ChromB was calculated by dividing the B value by the sum of the R, G and B 
values. All measurements were background corrected by subtracting the ChromB 
value of a white paper square submerged in distilled water and dried. In the case of 
sensor embedded glucose responsive backplates, the ChromB values were calculated 
from digital photographs of each backplate after an aliquot of glucose solution in PBS 
was added or the MN device had extracted glucose solution into the backplate. 
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2.4 Glucose detection using a hollow metal microneedle interfaced with an optical 
glucose sensor: the use of antioxidants to modulate signal response. 
2.4.1 Fabrication of custom needle holder and metal MN 
A custom made needle holder was fabricated from polypropylene plastic (Figure 5.3). 
The upper plate (diameter 30 mm) was cut to a thickness of 2 mm and four holes 
were drilled through the plate in a cross pattern using 200 µm diameter steel drill bit. 
A circular hole (diameter 30 mm) was made in the base plate in order to hold the 
upper plate in place when placed together. A screw was used to ensure a tight 
connection between the upper plate and base plate.  
BD Micro-Fine ™ Ultra 32G needles were removed from their outer packaging, placed 
in 100 mL of acetone and stirred for 4 hours in order to dissolve the adhesive holding 
the metal needles to their plastic housing. The needles could then be removed from 
the housing using tweezers. A needle was placed in each of the four holes on the 
upper plate of the needle holder, with the shorter bevelled end pointing downwards 
(Figure 5.4). The upper plate was then screwed on to the baseplate. A pair of cutting 
pliers was used to cut the metal needles to approximately 4 mm in length before the 
remaining length of needle was removed using abrasive sand paper. P600 grade 
paper was used to remove the majority of the excess material before P1000 grade 
paper was used to remove the final 0.5 mm to avoid unwanted burrs or imperfections 
along the edges of the needle that could form blockages. The holder was then 
disassembled and the needles were removed from the upper plate using tweezers. 
100 µm diameter steel wire was threaded through each of the cut needles to remove 
material that had plugged the lumen and to ensure they remained open. They were 
then rinsed with acetone and dried at RT for 10 mins to yield 2 mm long 32G needles. 
2.4.2 Fabrication of the metal MN and photopolymer baseplate 
A master mould was 3D printed using the Form 1+ printer in clear resin (Figure 2.2a). 
RTV silicone was prepared as detailed in Section 2.3.2, poured into the master mould 
and allowed to cure for 16 h at 25°C. It was then removed from the master, washed 
with ethanol and dried to yield the negative silicone mould for the photopolymer 
baseplate. 100 µm diameter wire was threaded through a 32G BD needle which was 
pierced through the centre of the negative mould so that the wire was perpendicular 
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to the surface of the mould. The full size needle was then removed, leaving the wire 
in place.  A 2 mm long needle was then threaded down the wire with the needle point 
facing upwards until the lower end reached the silicone mould (Figure 2.2b). 200 µL 
of TRIM containing 0.1% w/w of Irgacure 184 as a photoinitiator was pipetted into 
the mould and polymerised by placing under a 365nm emitting UV lamp (6W, 50Hz, 
0.12 A) for 60 mins. The MN and baseplate was then removed from the mould, 
washed with methanol and dried at 60°C for 10 mins.  
 
 
 
 
(a) 
(b) 
Figure 2.22: (a) Master mould produced using Clear resin (proprietary) using Form 1+ 3D printer. (b) 
Schematic using master mould to create negative silicone mould. This was then used to hold 2 mm needle 
in place for the formation of the surrounding baseplate to produce the metal MN. 
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2.4.3 Fabrication of PDMS suction housing and assembly of the metal hollow MN 
device 
A master mould was printed using the Form 1+ printer in clear resin, washed in 
isopropanol and then dried. PDMS (Sylgard 182 Silicone Elastomer, Dow Corning) was 
prepared according to the manufacturer’s instructions. This involved mixing the base 
and catalyst in a 10:1 ratio (w/w) in a 50 mL polypropylene tube and mixing 
thoroughly with a disposable glass stirrer. The tube was then placed in a vacuum oven 
and air bubbles removed by applying a vacuum force for approximately 60 mins. The 
PDMS was then poured into the master mould to minimise entrapped air pockets. 
The filled moulds were then placed in an oven overnight to cure at 100 °C. 
Subsequently, the PDMS housings were removed from the moulds and washed with 
methanol and dried. In order to create the transparent PDMS housing as shown in 
Figure 5.13, the centre surface of the 3D printed master mould was covered with a 
glass microscope slide. In order to ensure sufficient adhesion to the mould, the 
underside of the glass slide was roughened with sand paper before the application 
of cyanoacrylate glue. The glue was allowed to completely dry before addition of the 
PDMS liquid and the housing was fabricated as previously described above. 
To assemble the MN devices, the PDMS housings were affixed to photopolymer 
baseplates containing the metal MN as described in Section 2.4.2 using 
cyanoacrylate glue. Sensor backplates or blank paper squares were placed on the 
back of the baseplates before attachment of the PDMS housing. 
2.4.4 Photophysical investigation of the glucose sensor coupled with ascorbic acid 
A 50:50 ethanol and distilled water solution of 625 U/L GOx, 125 U/L HRP and 3.33 
mM TMB was prepared. Sufficient quantities of ascorbic acid (AA) was added to 
aliquots of the sensor solution to give a final concentration of either 0 µM, 20 µM or 
40 µM AA. 5 µL of aqueous glucose solution (7.5 mM or 10 mM) was added to each 
sensor solution and the absorbance at 650 nm was determined using UV-Vis 
spectroscopy at 10 s intervals for 5 mins. 
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2.4.5 Glucose sensor embedded paper backplates modified with AA  
10 mm2 paper squares were submerged in an ethanol / distilled water solution (50:50 
v/v) containing 6250 U/L GOx, 1250 U/L HRP and 3.33 mM TMB for 5 mins before 
removal and drying at 25 °C for 1 h. The paper backplates were then dipped in 
aqueous solutions of AA (0 – 10 mM) before a further drying step at 25 °C for 1 hr. 
To each backplate was then added 1 µL of either 7.5 mM or 10 mM of a glucose 
solution in PBS. Digital photographs of the backplates were then taken after 60 s 
(Figure 5.16). A further experiment was subsequently undertaken where sensor 
embedded backplates containing 5mM AA were photographed every 60 s for 5 mins 
after the addition of 1 µL of 0.0 mM – 20 mM aqueous solutions of glucose (Figure 
5.17).  
2.4.5 In vitro extraction of glucose solutions using the assembled metal hollow MN 
with AA modified glucose sensor backplate 
Metal hollow MN devices with 5 mM AA sensor backplates were assembled as 
detailed in Section 2.4.3. Two glass slides were fixed to the surface of a 90 mm petri 
plate to act as a scaffold for the MN device. The petri plates contained 30 mL of 
glucose solution in PBS ranging from 0 – 20 mM . A gap of approximately 2 mm was 
left open between the slides to allow access to the glucose solution in the plate 
(Figure 5.10). The MN device was pierced through a single layer of Parafilm and 
placed on top of the two glass slides with the extruding MN touching the glucose 
solution. The flexible PDMS housing was pressed and released using finger pressure 
in order to extract the glucose solution into the device. The devices were 
photographed at 30 s intervals for 120 s to observe the colour change on the sensor 
embedded backplates. 
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Chapter 3 
3.0 Polymeric Hydrogel Microneedles for the Extraction and Optical 
Detection of Glucose 
3.1 Introduction 
As discussed in Chapter 1, frequent glucose monitoring is a key requirement for the 
effective management of diabetes. The exchange of glucose and other biological 
analytes between the plasma present in the capillaries near the surface of the skin 
with the extracellular fluid compartment and ISF allows an opportunity to access 
these analytes without the need for blood sampling. As glucose levels found in the 
ISF correlate well with those found in the plasma, with a mean absolute difference 
of approximately 10%136,137, the measurement of glucose within the ISF provides an 
indirect measurement of the glucose present within the blood capillaries and can be 
used in the monitoring of hyperglycaemia in diabetes.  
3.1.1 ISF monitoring using microneedles 
As discussed in Section 1.11 there have been a wide range of MN based methods 
investigated to remove ISF from the skin in order to gain access to the analytes 
within. One of the most promising approaches are MNs prepared from swellable 
hydrogels composed of PMVE/MAH and PMVE/MA crosslinked with PEG138.  These 
MNs can penetrate the stratum corneum in the dry xerogel state and absorb ISF that 
can be subsequently be removed and analysed. The MNs have demonstrated the 
ability to be removed from the skin intact after application therefore leaving no 
polymer residue behind. This is an important consideration in ensuring the 
biocompatibility of the system. A further advantage of PMVE/MA based MNs is the 
decreased chance of needle stick injuries as after removal from the skin the MN 
projections are unable to re-penetrate skin due to the absorption of the fluid.  
3.1.2 Poly(methylvinylether/maleic acid)  MNs 
In an effort to increase the swelling capabilities of the hydrogel, sodium carbonate 
has been added to the formulation as a modifying agent139. The sodium carbonate 
acts by neutralising a proportion of free carboxylic acids present on the maleic acid 
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subunits of the backbone, thus providing less opportunities for the esterification 
reaction of the PEG to form crosslinks with the backbone. This decreased crosslinking 
density results in an increase in the swelling capability of the hydrogel. A balance 
must be maintained however, as when the crosslinking density is decreased 
sufficiently by the addition of a large amount of sodium carbonate, the hydrogel will 
lose its swelling capability and become soluble.  
3.1.3 Extraction and determination of glucose concentration  
Current approaches to determining the analyte concentration contained within 
PMVE/MA MNs involve post processing steps. The ISF is removed from the MN either 
by centrifugation128 or by adding the MN to water and allowing the analyte to diffuse 
out of the swollen MN and into the surrounding solution10 . The concentration of the 
analyte can then be determined using various methods such as HPLC, 
electrochemical glucometers or enzymatic assays129. These “off board” analytical 
steps have the disadvantage of requiring external equipment, trained users and 
complex steps that preclude these from being used in a POC device in their native 
form. An integrated device that permits the MN to perform in situ analysis bypasses 
these drawbacks and would allow these MNs to become point of care devices that 
patients could use without training to determine clinically relevant measurements 
related to disease. 
 
3.1.4 Colorimetric Determination of Glucose Concentration 
Visual determination of a colour change is one possible way of enabling a result to 
be determined without the need for external equipment. Such colorimetric tests for 
glucose have been widely used commercially, paired with a calibrated colour chart 
for the determination of glucose in urine140 (e.g. Clinistix®). These tests rely on the 
glucose oxidase catalysed metabolism of glucose to produce gluconic acid and 
hydrogen peroxide. The hydrogen peroxide is then used to oxidise a dye to produce 
a colour change. 3,5,3',5'-tetramethylbenzidine (TMB) is one such dye and can be 
used to detect the resultant hydrogen peroxide by forming the one electron oxidised 
blue colour charge transfer complex when catalysed by a peroxidase enzyme141. This 
blue coloured compound can then be further oxidised to the two electron oxidised 
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yellow diimine derivative (Figure 3.1). Subsequently, the amount of glucose present 
in the sample can be determined by correlating with the intensity of either the blue 
or yellow colour change.  
 
Figure 3.1 Scheme of the oxidation of TMB by hydrogen peroxide producing blue charge transfer 
complex and yellow diimine. 
 
After a single electron oxidation TMB is converted to a radical cation which forms an 
equilibrium with the blue coloured charge transfer complex. After a further 
oxidation, the charge transfer complex is converted to the yellow diimine form.   
3.2 Aim and Specific Objectives 
The main aim of the work undertaken in this chapter was to develop a hydrogel based 
MN device capable of penetrating skin and swelling with ISF containing glucose. A 
colorimetric sensor will be integrated with the MN to allow the visual determination 
of glucose concentration.  The specific objectives were: 
i. Investigate the swelling capabilities of hydrogels prepared from 
poly(methylvinylether/maleic acid) and crosslinked using poly(ethylene) 
glycol at various crosslinking densities. 
ii. Manufacture highly swellable hydrogel MN arrays from the polymers 
prepared in (i) above. 
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iii. Develop an optical detection system (hereafter referred to as sensor) for 
physiologically relevant concentrations of glucose. 
iv. Develop a suitable matrix for the sensor enabling it to be interfaced with 
the hydrogel MN to produce an integrated device. 
v. Investigate the ability of the integrated MN-sensor to determine glucose 
concentrations in solutions simulating ISF. 
3.3 Results and Discussion 
3.3.1 Swelling studies of PMVE/MA hydrogels crosslinked with PEG 
To investigate the effect of altering crosslinking density with sodium carbonate, three 
PMVE/MA hydrogels were prepared. Each formulation contained PMVE/MA (20% 
w/w), PEG (7.5% w/w) (MW 10,000 Da) and sodium carbonate at either 0%, 3% or 
5% w/w (polymers 1 2 and 3 respectively) with the remaining mass balance 
comprising distilled water.  
Following dissolution, the separate solutions were centrifuged at 1000 x g to remove 
air bubbles and cast in thin films using a 13 mm x 13 mm moulds. These films were 
left to dry at ambient temperature for 48 hours then placed in an oven at 80°C for 24 
hours. This allowed the polymer backbone to become crosslinked through ester bond 
formation between the carboxylic acid residues of the maleic acid subunits and the 
terminal hydroxyl groups on PEG as shown in Figure 3.2. After crosslinking, the 
squares of each film were submerged in phosphate buffered saline (PBS) and 
Figure 3.2 Scheme of crosslinking reaction between PMVE/MA and PEG 
Equation 3.1 Percentage swelling of polymer formulations in PBS 
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periodically removed, dried with filter paper and weighed to monitor the swelling 
characteristics. The percentage swelling was calculated using Equation 3.1: 
% Swelling =  
mt − m0
m0
 x 100 
Where mt is the mass at each time interval and m0 is the starting mass of each film. 
The results, shown in Figure 3.3, illustrate that the formulation without sodium 
carbonate reached a percentage swelling at equilibrium of 2676% w/w ± 488%.  The 
inclusion of 3% sodium carbonate significantly increased this to 7343% w/w ± 1071% 
at equilibrium (p < 0.01 at 5h). The formulation containing 5% sodium carbonate did 
not swell with PBS but rather dissolved after a few minutes.  
 
Figure 3.3 Plot showing swelling of 1cm x 1cm films of PMVE/MA based hydrogels. 5% sodium 
carbonate formulation dissolved. Error bars represent standard deviation where n = 3. ** p < 0.01 for 
polymer 2 v polymer 1 at 5 h.  
 
The differences in the swelling characteristics of the three formulations can be 
explained by changes in crosslinking densities. Polymer 1 would be expected to have 
the highest cross-link density and so imbibed the least fluid at equilibrium. The 
inclusion of 3% sodium carbonate in polymer 2 would result in a proportion of the 
free carboxylic acid groups of the maleic acid residues forming the sodium salt, 
reducing the number available to   form cross links resulting in a less stiff, less dense 
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gel.  As a result, the gel was able to swell with more fluid. In polymer 3, given the 
increased amount of Na2CO3 there were too few free acid residues remaining to form 
adequate crosslinking for swelling, instead rapidly dissolving in the aqueous medium.  
Based on these results, the formulation of polymer 2 was chosen for future studies, 
as it exhibited the highest rate of swelling and maximum swelling at equilibrium. The 
next step was to examine the feasibility of manufacturing MNs using this formulation.  
3.3.2 Manufacture of MNs prepared using polymer 2. 
Templates purchased from Micropoint® Technologies were used to create MN arrays 
from the chosen hydrogel formulation. The templates were designed to produce 10 
x 10 MN arrays with projections 350 µm in length. The MNs were manufactured by 
casting the blend of PMVE/MA, PEG and sodium carbonate into the templates 
followed by centrifugation at 800 x g for 10 mins to force the solution into the needle 
tips. The polymer in the templates was allowed to dry at ambient temperature for 48 
hours and then placed in an oven at 80°C for 24 hours. The MN arrays were removed 
from the templates after cooling to room temperature (Figure 3.4).   
 
The MNs consisted of a 10 x 10 array of square based pyramidal MN projections. Each 
projection had a height of 348 µm ± 10.2 µm and base width 160 µm when measured 
by light microscopy (Figure 3.5). The base to base interspacing was measured as 445 
µm and tip to tip distance as 590 µm.  
Figure 3.4 Digital photographs of 10 x 10 array of hydrogel MNs prepared from polymer 2 on fingertip. 
Left shows profile view and right shows view from above. 
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The MNs displayed well-formed MN projections, however, the opposite face of the 
baseplate had an uneven surface with sidewalls of hydrogel as a result of the 
moulding process. To produce MNs with an even baseplate and no sidewalls a 
“double filling” method was developed (Figure 3.6). 
 
 
 
 
 
 
  
This involved adding 60mg of polymer 2 solution to each mould and centrifuging. This 
was left to dry before a second layer of pre-gel solution was added until the solution 
had completely filled and just  flowed over the lip of each mould. After a second 
Figure 3.5 Optical microscope image of PMVE/MA hydrogel MN array. Profile view (left) and top down 
view (right).  Scale bar is 200 µm 
Figure 3.6 Schematic representation of MN "double fill" manufacture (i) Pre-gel blend added to mould, 
centrifuged and allowed to dry (ii) Second fill of pre-gel blend added to mould until slightly overflowing 
and allowed to dry (iii) MN crosslinked in oven then removed from mould (iv) Excess material trimmed 
from backplate 
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drying step, the MNs were placed in the oven at 80°C for 24 hours as before and then 
removed from the moulds. The MNs were then trimmed to remove any material that 
had been overflowed onto the lip of each mould. This resulted in MNs with a more 
even baseplate which was an important consideration when attaching the backplate 
containing the sensor.  The uniformity of mass for ten MNs using each method was 
determined (Figure 3.7). The average final mass of the single filled MNs was 18.3 mg 
± 0.68 mg whereas the double filled MNs was 60.6 mg ± 4.83 mg. The MNs made with 
the double filled method consisted of more polymer as was expected and had a 
greater variation in weight however this was deemed as an acceptable consequence 
due to the advantage of the even surface to which backplates could be attached in 
subsequent development.  
 
Figure 3.7 Scatter plot of final dried mass of MNs produced from single fill and double fill methods. 
Error bars represent standard deviations where n=10.  
 
The ability of these MN array to penetrate the skin was investigated by using Parafilm 
M® as a surrogate membrane. Parafilm has previously been used as a model 
membrane for MN skin insertion studies142,143 and closely resembles neonatal 
porcine skin with regards to penetration depth. MN arrays were inserted into five 
layers of Parafilm using firm thumb pressure and held in place for 30 s. The top layer 
of Parafilm was then removed with the attached MN remaining pierced through. The 
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Parafilm pierced MN was then examined using light microscopy to confirm that the 
MN tips had had successfully penetrated the film and remained intact (Figure 3.8).  
Figure 3.8 Optical microscope image of 350 µm MN tips pierced through a single layer of parafilm. 
Scale bar is 250 µm 
 
The mean length of each projection that was visible after penetration was 103 µm ± 
12.2 µm which was approximately 30% of the total projection length. Having 
confirmed the ability of the highly swellable MNs to penetrate through the model 
Parafilm membrane, the next step was to develop the glucose sensor that could be 
interfaced with the MN. 
3.3.3 Development of the glucose sensor. 
Colorimetric glucose sensors commonly rely on the enzymatic oxidation of glucose 
to produce gluconolactone and hydrogen peroxide (H2O2) (Figure 3.9).  
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Figure 3.9 Reaction scheme of the oxidation of glucose by Glucose Oxidase to produce Hydrogen 
Peroxide 
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The peroxide, catalysed by a peroxidase enzyme, is then used to convert a colourless 
dye to a coloured form as described in Section 3.1.3. In this way the concentration 
of glucose can be determined from the intensity of the coloured species.  
To determine the kinetics of this colour change reaction, an aliquot of glucose was 
added to a solution of glucose oxidase, horseradish peroxidase and TMB in sodium 
acetate buffer (pH 5.4) at room temperature. The absorbance spectrum of the 
solution was measured over the course of the reaction and plotted in Figure 3.10.  
 
 
Figure 3.10 Absorbance spectra obtained following oxidation of TMB (42 µM) by hydrogen peroxide 
produced from oxidation of glucose by GOx/HRP (425 U/L). Measurements taken at 60 s intervals. 
 
Initially, the absorbance at 270 nm corresponding to the colourless TMB was high, 
which decreased as the reaction progressed. The colourless TMB was converted to 
the blue coloured charge transfer complex (λMAX 650 nm) which rapidly increased 
intensity until it plateaued after 8 mins. This absorbance at 650 nm then began to 
decrease as more H2O2 was produced that further oxidised the blue complex to the 
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yellow coloured diimine. As a consequence, the decrease in absorbance intensity at 
650 nm was accompanied by the appearance of a new absorbance band centred at 
370 nm which continued to grow until the reaction was stopped at 15 min.  
Given that the goal was to use this sensing system as a method to determine 
variations in glucose concertation, it was of interest to identify the time taken for the 
absorbance readings to reach their maximum, as a practical device would require the 
colour change time to be kept at a minimum.  As the blue coloured complex was the 
dominant species in the solution, the absorbance at 650 nm was plotted separately 
as a function of time in Figure 3.11. As can be observed, using this particular ratio of 
enzymes to TMB, the formation of the blue charge transfer complex reached its peak 
after 8 min.   
 
Figure 3.11 Absorbance values of solution containing GOx/HRP (425 U/L) and TMB (42 µM) in sodium 
acetate buffer (pH = 5.4) at 650 nm showing formation of charge transfer complex over 15 mins. Error 
bars represent standard deviation where n=3 
 
To determine if the rate of blue charge transfer complex formation could be reduced, 
the concentration / ratio of enzymes and TMB were modified, with the absorbance 
at 650 nm measured over the course of 15 min.  Figure 3.12 shows the results when 
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the TMB concentration was kept constant but the concentration of the enzymes 
were doubled to 850 U/L. The results reveal that the peak charge transfer complex 
concentration is reached in a shorter period of time (3 mins) while the maximum 
absorbance intensity remained unchanged. In contrast, if the TMB concentration was 
doubled to 84 µM and the enzyme concentration kept constant, the time to reach 
peak absorbance at 650 nm was extended because the rate of oxidation was not 
increased. If both the enzyme and TMB concentrations were increased to 850 U/L 
and 84 µM respectively the peak absorbance was still reached in 8 mins, but the 
intensity of absorbance at 650 nm was increased to 0.86 indicating more charge 
transfer complex was formed. 
 
 
Figure 3.12 Absorbance at 650 nm showing formation of charge transfer complex over 15 mins using 
different ratios of GOx/HRP and TMB 
 
When increasing concentrations of glucose (0 – 1000 µM) were added to GOx/HRP 
(425 U/L) and TMB (42 µm), the plot of absorbance at 650 nm showed a linear 
relationship (R2 = 0.99) when measured at 8 mins between 0 – 200 µM (Figure 3.15), 
however this linearity broke down at higher concentrations (200 – 1000 µM) as 
shown in Figure 3.13.  
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Figure 3.13 Absorbance values of solutions containing GOx/HRP (425 U/L), TMB (42 µM) and 
increasing concentrations of glucose (0 – 1000 µM) in sodium acetate buffer (pH = 5.4) Absorbance at 
650 nm shows formation of charge transfer complex. Absorbance at 460 nm shows formation of 
diimine. 
 
This loss of linearity can be explained by the formation of the second oxidation 
product, the yellow diimine. The distinctive colour change from blue to yellow has an 
intermediate green colour which is simply an approximately equal mixture of both 
structures (Figure 3.14). 
 
Figure 3.14 Photograph of solutions of GOx/HRP (425 U/L) and TMB (42 µM) spiked with increasing 
concentrations of glucose (0 - 1000 µm) in sodium acetate buffer (pH=5.4). Photograph taken after 8 
mins 
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To effectively use the blue colour present to determine the concentration of glucose 
visually, the intensity of colour must be directly proportional to the glucose 
concentration. This means that the sensor system using this ratio of GOx/HRP to TMB 
could be used to determine glucose concentrations between 0 – 200 µM, as the 
relationship between the absorbance and the glucose concentration had acceptable 
linearity over this range. (Figure 3.15). 
Figure 3.15 Plot of linear range of absorbance at 650nm at 8 mins after addition of increasing 
concentrations of glucose to GOx/HRP (425 U/L) and TMB (42 µM) in sodium acetate buffer (pH = 5.4) 
 
To extend the linearity range and thus the range of glucose that could be detected 
visually, the formation of the yellow coloured diimine must be avoided when 
measuring higher concentrations of glucose within the given time frame. As the 
diimine is formed through the second oxidation of the blue charge transfer complex, 
reducing the rate of oxidation can reduce its likelihood to form. One way to decrease 
the rate of oxidation was to decrease the concentration of the GOx/HRP but keep the 
concentration of TMB constant. Adopting this approach, Figure 3.16 shows that the 
R2 = 0.99 
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linear region can be extended across the entire 0 – 1000 µM range by decreasing the 
concentrations of GOx/HRP from 425 U/L to 106 U/L. 
Figure 3.16 Absorbance of solutions containing 425 U/L, 212 U/L and 106 U/L of GOx/HRP and TMB 
(42 µM) 8 mins after addition of increasing concentrations of glucose in sodium acetate buffer 
(pH=5.4) 
 
This decreased the formation of the diimine within the 8 mins despite the higher 
concentrations of glucose.  From these experiments it was concluded that the ratio 
of the enzymes GOx/HRP to the concentration of TMB could be varied to control 
range of glucose concentration that could be determined by monitoring the 
formation of the blue coloured charge transfer complex. By finding the correct ratio 
of GOx/HRP to TMB the intensity of the blue colour formed at a given time point 
could be used to determine glucose concentration within the physiological range (0 
- 10 mM). However, the kinetics of this reaction would vary depending on the 
substrate in which it occurred. As it was carried out in an aqueous buffer at pH 5.4 it 
was deemed not essential to find the correct ratio of GOx/HRP to TMB to show a 
linear colour change within the physiological glucose concentration at this point as 
this would change when the reaction was carried out in a different substrate such as 
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a hydrogel or solid matrix, which would be necessary to interface with the hydrogel 
MN. 
3.3.4 Interfacing sensor with hydrogel MN  
The matrix chosen to house the sensor system was required to have excellent water 
transfer abilities, be compatible with pH sensitive and thermolabile enzymes and 
have the ability to be integrated with the hydrogel MNs. The PMVE/MA hydrogel was 
initially considered as a candidate to create a hydrogel backplate that could be 
attached to the opposite face of the baseplate from the MN projections as it had 
been demonstrated to be highly swellable. While the enzymatic glucose sensor did 
remain active when added to the pre-gel blend of PMVE/MA and PEG, as 
demonstrated by the addition of 10 mM glucose solution (Figure 3.17), the act of 
heating the polymer after drying to induce chemical crosslinking rendered the 
enzymes inactive.  
 
The addition of the enzymatic sensor to the hydrogel after crosslinking was possible 
by submerging a crosslinked xerogel in a solution containing the sensor and allowing 
the hydrogel to imbibe the fluid. After it had become fully swollen, surface water was 
removed with filter paper and a 10mM glucose solution was pipetted on to the gel. 
A colour change was observed with the yellow diimine being visible (Figure 3.18). 
Figure 3.17 Digital photographs of pre-gel blends containing GOx/HRP and TMB (a) before addition of 
glucose (b) 4 mins  after addition of 10mM glucose (c) 8 mins after addition of 10 mM glucose 
(a) (b) (c) 
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Figure 3.18 Digital photographs of addition of GOx/HRP and TMB to crosslinked hydrogels to produce 
colour change after glucose. (a) Crosslinked PMVE/MA based hydrogel in dried state (b) swelling 
hydrogel in aqueous solution containing GOx/HRP and TMB (c) swollen hydrogel 5 mins after addition 
of 10 mM glucose 
 
In order to prepare a backplate from the sensor swollen xerogel, it was allowed to 
dry at ambient temperature under a constant air flow to aid evaporation for 4 hours.  
The resultant film was then cut to size and attached to the back on a hydrogel MN 
with a small amount of distilled water to aid adhesion (1 µL). The MN-sensor 
backplate assembly was then pierced through a layer of Parafilm and placed on top 
of a 10 mM glucose solution (Figure 3.19). This in vitro experimental set up was used 
as a simple method to determine if the MN tips could swell with sufficient solution 
to transfer the glucose into the backplate and interact with the sensor to produce a 
colour change.  
 
Figure 3.19 Schematic diagram of in vitro experimental set up to investigate the ability of PMVE/MA 
MN with hydrogel backplate containing glucose sensor to extract solution from reservoir containing 
10 mM glucose 
(a) (b) (c) 
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Figure 3.20 shows the results of this study with a blue/green colour change observed 
in the backplate after 60 min, which indicated that the enzymes remained active 
following incorporation within the dried polymer film. In Figure 3.20, the backplate 
was covering only a portion of the MN baseplate and the colour was only observed 
in that region. 
 
 
While using this method to form a backplate did show some encouraging results, 
there was a number of issues in using PMVE/MA crosslinked with PEG. The need to 
swell the polymer with the sensor and then allow it to dry meant it was difficult to 
control the shape and texture of the resultant film. A simpler method would involve 
the incorporation of the glucose sensor into the polymer before casting it into a 
mould and drying to allow the production of films with predetermined dimensions. 
This would require a polymer film that could be created without the need for 
elevated temperatures and with a pH of between 4 and 7. One such polymer film 
consists of PMVE/MA and TPME. This film was produced by adding TPME to a 
solution of PMVE/MA and adjusting the pH to 5.4 using NaOH. To this solution was 
added GOx/HRP and TMB which was then cast into the MN moulds to match the 
exact dimensions of the hydrogel MNs. Importantly, the moulds were not centrifuged 
after addition of the solution in order to produce polymer film squares that did not 
have MN projections. These backplates were allowed to dry under constant air flow 
Backplate 
Figure 3.20 Digital photograph of PMVE/MA MN with hydrogel backplate containing GOx/HRP and 
TMB pierced through Parafilm and placed on top of aqueous solution containing 10mM glucose (a) 
line showing partial coverage of baseplate with hydrogel backplate (b) after swelling with aqueous 
solution containing 10 mM glucose and production of blue/green colour change 
(a) (b) 
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and attached to the MN baseplate as before.  When tested in vitro as in Figure 3.19, 
a green colour was observed once more, but it still required approximately 50 mins 
(Figure 3.21).  
The addition of TPME to the PMVE/MA has been used previously as a plasticiser to 
increase the flexibility of the film rather than a crosslinker144. Indeed, the structure 
of TPME (Figure 3.22) shows the presence of only one free hydroxyl (-OH) group.  
 
CH3
O
CH3
O
CH3
O
CH3
OH
 
Figure 3.22 Structure of TPME used as a plasticiser in the PMVE/MA film 
 
As a result, no covalent crosslinks could be formed between the separate PMVE/MA 
backbones, unlike with PEG. This resulted in a flexible film which remained water 
soluble and thus absorbs less fluid before dissolving.  
Figure 3.21 Digital photograph of PMVE/MA MN with PMVE/MA and TPME based backplate covering entire 
baseplate area (a) before swelling (b) after swelling for 50 mins 
(a) (b) 
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3.3.5 Optimisation of hydrogel MN with backplate in vitro 
While the integration of the sensor and MN successfully generated a colour change 
in response to glucose after 50 mins, for a point of care device it is preferable for the 
results to be available extremely rapidly, for example after 60 seconds. To achieve 
this goal, the following two limitations of the device were identified:  
(i) The rate at which the backplate absorbed the solution and produced a 
colour change. 
(ii) The rate at which the MN imbibed the solution. 
Both of these limitations were investigated in turn for further optimisation. 
3.3.5.1 Improving the rate at which the backplate absorbed the solution and produced 
a colour change.  
It was observed that the hydrogel polymer backplates did provide a substantial delay 
in the time between the MN swelling and the colour change occurring, therefore 
other platforms to house the glucose sensor rather than hydrogel based backplates 
were investigated. Paper was identified as an ideal candidate due to its low cost, 
excellent water transporting capabilities and widespread use in colour based 
sensors145. The initial white colour of the paper provided an excellent contrast for 
colour intensity to be determined by the naked eye and aqueous solutions are quickly 
drawn into dried paper networks through capillary action between the 
interconnected strands of paper fibres146.  
To create sensor embedded paper backplates, paper squares (Whatman No. 1 filter 
paper) measuring 1cm2 were submerged in solutions of GOx/HRP and TMB (50:50 
distilled water: ethanol) for 5 mins. The backplates were then removed and allowed 
to air dry at room temperature for 60 mins. An experiment was conducted to 
determine the ideal concentrations of GOx/HRP and TMB to be used. The goal was 
to achieve a rapid colour change that was easily visible to the naked eye within 30 s 
to shorten the time to response. Four formulations were investigated as seen in 
Table 3.1. To observe the response of each backplate, an aliquot (5 µL) of a 10 mM 
glucose solution was added and photographs of each backplate at defined time 
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points were taken. The experiment was repeated and both sets of photographs at 0s, 
30s and 60 s from are shown in Figure 3.23. 
Table 3.1 Four formulations used to produce glucose responsive paper backplates 
Formulation GOx (U/L) HRP (U/L) TMB (mM) 
A 8.5 1.7 3.33 
B 85 17 3.33 
C 850 170 3.33 
D 8500 1700 3.33 
 
Figure 3.23 Digital photographs of colour change in paper backplates produced using formulations A 
– D over time following addition of a 5 µL aliquot of 10 mM glucose. Results shown from two repeats 
(left and right). 
 
Both formulations A and B generated little to no visible colour change within 60 s. An 
easily visible colour change was visible with formulation C after 30 s and this 
increased in intensity at 60 s. Formulation D caused a rapid colour change, however, 
the colour was less uniform and less easily visible. As each formulation had the same 
concentration of TMB the differences observed must have been due to the enzyme 
Repeat 2 Repeat 1 
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concentration. Formulations A and B had a low concentration of GOx and HRP and, 
therefore, relatively little TMB was oxidised within 60 s. It was observed that at later 
time points, e.g. 8 mins (Figure 3.24) a colour change did occur with both 
formulations, with B providing a more intense change. 
 
Figure 3.24 Digital photographs of paper backplates made from formulation A and B 8 mins after 
addition of glucose showing colour change 
 
Formulation C showed the most promising results as a visible colour change was 
produced at 30 s that was reasonably uniform and covered the entire backplate. The 
non-uniformity of the colour change in D may be explained by the extremely high 
concentration of GOx and HRP forming a suspension in the solution used to make the 
backplates, resulting in uneven deposition of the enzymes across the backplate. C 
was chosen as the lead formulation to pair with the 350 µm hydrogel MN to retest in 
vitro and determine any improvement in performance. 
Paper backplates prepared using formulation C were attached to the back of 
hydrogel MNs and the time taken for a colour change to occur using the previous in 
vitro method was measured. A decrease from the previous time (50 mins) using the 
hydrogel backplate was observed with the initial wetting of the backplate appearing 
after a mean time of 28.5 mins ± 3.9 mins from placing the MNs in contact with the 
10 mM glucose solution through Parafilm. The fluid was observed to contact the 
paper backplate from a single point and quickly became dispersed throughout the 
entire backplate due to capillary action inherent to the material (Figure 3.25). The 
blue colour change began to occur as the TMB was oxidised within 60 s from the 
initial wetting. From these results, paper was identified as a suitable platform to 
house the glucose sensor for subsequent studies as it produced a colour change 
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within a much shorter period of time compared to previous hydrogel backplates and 
due to the facile nature of producing a large quantity of backplates with relatively 
low cost. 
 
Figure 3.25 Digital photographs of paper backplates attached to 350 µm MN pierced through parafilm 
and placed on 10 mM glucose solutions (a) initial wetting of backplate (b) 20 s after wetting (c) 40s 
after wetting (d) 60s after wetting 
 
3.3.5.2 Improving the rate at which the MN imbibed the solution. 
Following the identification of a MN sensor backplate with rapid colour change 
kinetics, attention was turned to improving the extraction capabilities of the hydrogel 
MN. Some initial optimisation was achieved by using sodium carbonate as a 
crosslinking density modifier, thus increasing the rate of swelling. However, 
additional steps were required to shorten the time to response further. Considering 
the dimensions of the MN, the length of the MN projections were thought to be a 
significant factor in the rate at which fluid would be imbibed into the MN baseplate 
and subsequently the backplate. Previously, it was be determined that an average of 
103 µm of each MN projection penetrated through the parafilm membrane and, 
therefore, only this portion would be in contact with the aqueous solution. By 
increasing the length of the MN projections, a greater amount of the swellable 
hydrogel would be exposed to the solution and the rate of uptake may be increased. 
When applied to an in vivo system i.e. human skin, the MN projections would 
penetrate further into the viable epidermis and upper layers of the dermis and so 
contact more ISF.  
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To this end, moulds to produce MN arrays of increased length were purchased. The 
mould specifications listed a length of 800 µm. These MNs were produced in the 
same manner as the shorter MNs using polymer 2 (Figure 3.26).  
 
Light microscopy was used to confirm good replication from the moulds with a mean 
needle length of 803 µm ± 15.6 µm and mean base width of 335 µm. (Figure 3.27). 
Base to base interspacing of 288 µm and tip to tip distance of 588 µm. 
 
 
 
 
 
 
 
 
 
 
Figure 3.27 Light microscope image of PMVE/MA hydrogel MN with 800 µm length MNs. Scale bar is 
200 µm 
 
The MN arrays were also pierced through Parafilm and photographed as before 
(Figure 3.28). It was confirmed that the projections did penetrate while remaining 
intact. When comparing the length of each projection exposed after piercing through 
(a) (b) 
Figure 3.26 Photographs of Polymer 2 PMVE/MA hydrogel MNs (a) 350 µm MN length   (b) 800 µm 
MN length 
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a single layer of Parafilm, a significant increase was observed for the longer MN with 
a mean of 235 µm ± 37.6 µm  compared to the shorter MNs that had a mean length 
of 103 µm ± 12.2 µm.  
 
 
Figure 3.28 Light microscope image of 800 µm MN tips penetrating through a single layer of parafilm. 
Scale bar is 200 µm 
 
To evaluate if increasing the length of the MN projection increased the rate of 
glucose extraction, glucose sensor embedded paper backplates were attached to the 
MN baseplate as before, pierced through a single layer of parafilm and placed on the 
surface of a 10 mM glucose solution. Initial wetting of the paper backplate occurred 
after 21.2 mins ± 3.6 mins following addition of the MN and the colour change 
occurred within the next 60 s as observed in the shorter MNs (Figure 3.29). 
 
Figure 3.29 Digital photographs of paper backplates attached to 350 µm MN pierced through parafilm 
and placed on 10 mM glucose solutions (a) initial wetting of backplate (b) 20 s after wetting (c) 40s 
after wetting (d) 60s after wetting 
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These results highlight that increasing the length of the MN projections from 350 µm 
to 800 µm reduces the time taken for the MN to extract the aqueous solution by 7 
mins from 28.5 mins ± 3.9 mins to 21.2 mins ± 3.6 mins. Figure 3.30 illustrates how 
the changes in the MN and backplate described in this chapter decreases the time 
taken to produce a colour change in the sensor backplate.  
 
Figure 3.30: Time for colour change to occur in glucose extraction in 350 µm length MNs arrays with 
TPME backplate, paper backplate and 800 µm length MNs with paper backplate. 
 
There have been a number of MNs with PMVE/MA used as the main copolymer with 
crosslinking polymers other than PEG. For example, hyaluronic acid (HA), a 
glycosaminoglycan, has been covalently crosslinked with PMVE/MA to form hydrogel 
MNs147. The polymer films demonstrated sustained release of methylene blue (MB) 
used as a model compound over 50 h. The polymer films also exhibited the ability to 
rapidly swell with aqueous solutions similar to the PMVE/MA and PEG hydrogels 
discussed in this chapter. In fact, the rate of swelling was greater in the HA containing 
polymer films as they reached their maximum equilibrium in 15 mins however the 
overall swelling capacity was substantially lower (1400% w/w) than the PEG 
containing polymer in this work.  
Pectin has also been used as a crosslinker in PMVE/MA based hydrogel MNs148. While 
the crosslinking mechanism was reportedly due to esterification between the free 
acid residues of the PMVE/MA and free hydroxyl groups present on the pectin 
macromolecules, the swelling rates of the polymer films were substantially slower 
then PEG crosslinked films. The swelling studies were conducted over 7 days with the 
maximum swelling percentage observed to be 4951% w/w.  While this is comparable 
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to the swelling percentage at equilibrium of the PEG crosslinked films, it is 
substantially slower in swelling rate.  
3.4 Conclusion 
In this chapter, highly swellable MN arrays composed of PMVE/MA, PEG and sodium 
carbonate were produced using a micromoulding technique. MN arrays with both 
350 µm and 800 µm projections in 10 x 10 arrays were successfully produced and 
were sufficiently robust to remain intact following penetration through a Parafilm 
membrane.  
An optical detection system for glucose was developed composed of GOx/HRP and 
TMB. The sensor utilised the production of hydrogen peroxide from the oxidation of 
glucose to produce a visible colour change. The oxidation of the TMB by the hydrogen 
peroxide was catalysed by HRP to form a blue coloured charge transfer complex. 
Upon further oxidation, the yellow coloured diimine species was observed. The 
sensor was interfaced with the MN, initially using a hydrogel backplate platform. 
These MNs were tested in vitro and successfully indicated the presence of glucose in 
simulated ISF within 50 mins, via a blue colour change that was visible to the naked 
eye.  
Multiple optimisation steps were undertaken in order to improve the overall time 
required for observation of the colour change following addition of the MN to a 
glucose solution. By optimising the ratio of sensor components (i.e. enzymes and dye 
etc.) and utilisation of a paper based substrate to house the sensor as a MN 
backplate,  the overall response time  was almost halved from 50 min to 28.5 mins ± 
3.9 mins. By increasing the length the MN projections from 350 µm to 800 µm, the 
time was further decreased to 21.2 mins ± 3.6 mins.  
While substantial improvement in the response time was achieved by these 
optimisation steps, for practical use as a POC device the response time must be 
extremely rapid. The major limitation observed was the time necessary for the 
PMVE/MA hydrogel MN to extract the aqueous solution and bring it into contact with 
the backplate. 
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In the following chapter, the use of a hollow MN was investigated to determine if the 
extraction kinetics could be improved when compared to the hydrogel MNs.  
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Chapter 4 
4.0 Single Hollow Microneedle Device for the Extraction and 
Colorimetric Detection of Glucose 
4.1 Introduction 
As identified in Chapter 3, one of the major challenges of designing POC MN device 
for glucose is the time taken for the hydrogel MN to imbibe fluid and transport it to 
the detection system. For a POC device, the measurement must be obtained within 
a reasonable time frame so the result accurately reflects the current analyte levels in 
the body. Glucose concentrations in the plasma and, therefore, the ISF can rapidly 
increase or decrease according to the insulin-glucagon cycle while the measurement 
from the MN is being obtained. Therefore, it is imperative that the measurement is 
obtained as quickly as possible after the test commences to ensure an intervention 
can be made if necessary. In this chapter, hollow MNs as an alternative to PMVE/MA 
hydrogel based MNs were investigated to determine their ability to rapidly transport 
simulated ISF to the detection system. 
Hollow MNs can made from monocrystalline silicon using MEMS technology. In one 
example, hollow silicon MNs that have successfully demonstrated the withdrawal of 
ISF from the skin in 15 – 20 mins using capillary action have been prepared125. These 
were manufactured by initially spinning a pattern of photoresist (SU-8) onto a silicon 
wafer leaving an array of circular areas of the silicon exposed. Then, using Deep 
Reactive Ion Etching (DRIE), channels that would become the lumen of the hollow 
MNs were etched into the wafer in the exposed silicon crystal. The MN projections 
were cut into columns by a micro-controlled diamond saw blade before sharpening 
of the columns into MN projections using an isotropic etching technique with a 
mixture of hydrofluoric, nitric and acetic acid. This produced 2D arrays of hollow MNs 
composed of silicon that were inserted into the skin of human subjects. The arrays 
were capable of extracting ISF, which was confirmed through optical microscopy and 
analysis of glucose in the fluid extracted.  
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Another method to prepare hollow MNs is through the use of metal 
electrodeposition149,150. Solid SU-8 MNs were prepared using photolithography with 
a dark exposure mask in the pattern of the 2D array of needles and UV light. The MNs 
were then fully coated with a conductive layer of poly (methyl methacrylate) and 
carbon black. In order to create open hollow MNs the arrays were exposed to O2/CF4 
plasma which eroded the conductive polymer away from the MN tips and exposed 
the SU-8 beneath. The arrays were then electroplated with nickel for structural 
strength and then gold for biocompatibility. This was achieved by submerging the 
conductive MN arrays in an electroplating bath and applying a voltage between the 
arrays and a metal electrode, which were composed of either nickel or gold. After 
the electroplating steps, the metal layers were separated from the other layers to 
create the hollow metal MN arrays.  
Both of these methods were successful in producing hollow MNs but require the use 
of highly specialised and costly materials and equipment. Silicone micromoulding 
may provide a more convenient and less costly method to create hollow MNs. 
However, the challenge of creating a master template from which to create the 
silicone mould must be addressed. In this chapter, the use of a hypodermic needle 
as a template in combination with 3D printing technology is investigated in order to 
develop a single hollow MN device.  
Additionally, a method to quantify the colorimetric response of the detection system 
was investigated in this chapter and involved recording digital photographs of the 
backplate followed by subsequent analysis using image processing software, ImageJ. 
This method compliments the use of naked eye detection as used in Chapter 3.  
4.2 Aim and Specific Objectives  
The aim of the work undertaken in this chapter was to prepare a hollow MN from 
polymerised glycidyl methacrylate (GMA) crosslinked with triethyleneglycol 
dimethacrylate (TEGDMA) and trimethylolpropane trimethacrylate (TRIM), hereafter 
referred to as 1. Subsequently, the MN was integrated with a paper-based 
colorimetric based GOx/HP and TMB glucose sensor and the kinetics of simulated ISF 
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withdrawal using this device was investigated. The ability of the device to accurately 
discriminate between various different glucose concentrations was also determined.  
The specific objectives were:  
i. Manufacture a hollow MN device composed of 1 that could transport 
simulated ISF containing glucose to the backplate 
ii. Determination of the kinetics of fluid withdrawal using the MN. 
iii. Mechanical analysis of the robustness of the MN structure. 
iv. Development of a method to quantify of the intensity of the blue colour 
change of the paper based sensor through digital image analysis using 
chromaticity.  
v. Optimisation of the sensor to produce a linear response to glucose in 
simulated ISF extracted by the hollow MN  
 
4.3 Results and Discussion 
4.3.1 Manufacture of a hollow MN device for the extraction of simulated ISF  
In order to produce a hollow MN, a Formlabs 1+ 3D printer was utilised to create the 
array. Initially, solid MN arrays were printed to investigate the ability of the printer 
to produce structures under one millimetre in length. Using computer aided drawing 
(CAD) software (SketchUp and Autodesk Nettfab) schematics of several solid MN 
arrays of various sizes were drawn and printed (Figure 4.1).  
 
                                Array 1     Array 2 
Figure 4.1 CAD images of solid MN arrays (Array 1) 1mm height, 1 mm base width, 1 mm interspacing 
and (Array 2) 1 mm height, 0.5mm base width, 0.5 mm interspacing 
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The printed arrays were examined using light microscopy to determine the 
dimensions of the projections and to evaluate the sharpness of MN tips (Figure 4.2). 
The projections of Array 1 had a mean height of 772.7 µm ± 90.9 µm and the 
projections on Array 2 had a mean height of 605.3 µm ± 42.9µm (n = 10). Both of the 
printed arrays showed a substantial difference in height from the original CAD 
schematics. Additionally, the tips of the projections were observed to be rounded or 
flattened. 
 
Figure 4.2 Optical microscope image of solid MN arrays projections produced using Formlabs 1+ 3D 
printer. Scale bars are 200 µm  
 
Direct printing of a hollow MN would require extremely high resolution to produce 
the sharp tip and the hollow lumen of the MN successfully. Therefore, following 
examination of this data from printing solid MNs it was concluded that it would not 
be feasible to produce hollow MNs using the FormLabs 1+ 3D printer due to its 
insufficient resolution.  
To overcome this challenge, instead of directly printing a hollow MN, a hypodermic 
needle was used as a moulding template. To produce a MN under 1000 µm in length, 
only the tip of the hypodermic needle was used as the template. To enable the 
replication of a set length of the needle, a housing for the needle was manufactured 
using the 3D printer as shown in Figure 4.3.  
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Figure 4.3 (Left) CAD schematic of housing to fix hypodermic needle. (Right) Housing to fix hypodermic 
needle printed using clear resin from Formlabs 1+ 3D printer 
 
As the needle was inserted into the housing, the length of the exposed tip was 
controlled with a removable lid. The dimensions of the lid were designed in such a 
way that the length of the needle exposed after insertion was 400 µm (Figure 4.4).  
 
Figure 4.4 Schematic of housing with hypodermic needle inserted with attached lid. The length of the 
needle exposed is controlled by the gap between the housing and the lid (400 µm). 
 
The templates were prepared as described in Section 2.3.1. The choice of polymers 
used to make the MNs was adapted from Lui et al.151 and consisted of polymerised 
GMA crosslinked with TEGDMA and TRIM (1). Lui et al. investigated the use of these 
methacrylate based polymers in conjunction with a PEG porogen in order to make a 
porous MN that had interconnected pores capable of fluid extraction using capillary 
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action. However, in this work, the porogen was excluded in order to form a solid 
robust structure that was not porous, opting instead for a single hollow lumen 
through the MN projection. 
Each MN was produced from the silicone templates as described in Section 2.3.2. 
Briefly, each mould was filled with 150 µL of 1 and a catalytic quantity of Irgacure 184 
as a photoinitator before irradiation with UV light to enable polymerisation (Figure 
4.5).  
 
Figure 4.5 Schematic of hollow MN production. Silicone mould is filled with 150 µL of photopolymer 
mix before irradiation with UV light. Hollow polymer MN is then removed from mould. 
 
To confirm each MN had remained hollow, a wire was threaded through the opening 
at the tip off each MN and through the baseplate. The MN projection was imaged 
using an optical stereomicroscope. This microscopy technique produced a 
stereoscopic view of the sample due to its binocular arrangement of lenses. It 
enabled the MN tip to be visualised without the need for more costly and less 
convenient electron microscopy. As seen in Figure 4.6, the MN produced had a sharp 
bevelled tip 400 µm in height, with the opening of the hollow bore clearly visible.  
 
365nm 
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Figure 4.6 Photographs of polymerised hollow microneedle devices. (a) Polymer microneedle with 
metal wire through hollow bore. (b) Micrograph image of hollow microneedle tip. 
 
4.3.2 Kinetics of fluid removal using the hollow MN device. 
To confirm the capability of the hollow MN to withdraw fluid rapidly, a blank paper 
backplate was fixed to the upper side of the MN baseplate. The needle end of the 
device was then pierced through a Parafilm membrane and the assembly placed onto 
a solution containing MB dye (1 mM).  The rate of MB uptake was followed visually 
over the course of 5 s. As observed in Figure 4.7, the first appearance of the dye 
occurred within 2 s and the backplate was completely saturated within 5 s. 
Figure 4.7 Digital photograph of single hollow MN device extracting MB solution (1 mM) into a blank 
paper backplate via capillary action over 5 s. 
 
Notably, it was also observed that the blue solution moved up through the hollow 
bore and into the centre of the paper backplate from where it then migrated toward 
the outer edges. This confirmed that the fluid was only transported though the 
hollow bore of the needle and not through the baseplate itself. Such a timescale is 
compatible with use in a POC device. 
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4.3.3 Mechanical testing of the hollow MN device 
To reliably penetrate the skin, the MN must be adequately robust to withstand the 
force necessary to penetrate without fracture. The mean axial force required to 
fracture the MN was measured to be 0.27 N ± 0.04 N (n = 4) by driving a steel rod 
onto the MN tip using an axial load test station (Figure 4.8). Previous reports have 
shown forces ranging between 0.028 N – 0.030 N per MN to be sufficient to penetrate 
the skin152. These values are approximately one order of magnitude lower than the 
mean fracture force of the hollow MN device. Therefore, the hollow MN should be 
sufficiently robust to withstand insertion into human skin. 
Figure 4.8 Representative graph of force against displacement of axial load fracture test of hollow MN. 
Mean force to fracture = 0.27 N ± 0.04 N (n = 4) 
 
4.3.4 Development of a method to quantify of the intensity of the blue colour change 
of the paper based sensor 
In order to more accurately develop the colorimetric sensor for glucose, a method to 
quantify the intensity of the colour change generated by the sensor was necessary. 
In Chapter 3, UV/Vis spectroscopy was used to quantify the concentration of the blue 
charge transfer complex in solution at 650 nm. However, this analytical method is 
more difficult when the sensor is incorporated into a solid matrix such as paper and 
requires the use of solid-sate probes in combination with a UV-Vis spectrometer. A 
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more convenient method to monitor the colour change in a paper matrix was to 
record photographs with a high resolution digital camera. Subsequently, the colour 
data could be extracted from the digital image using image processing software. 
Colours in digital images and screens can be represented using the trichromatic RGB 
model. The model is so named due to the three primary channels from which all other 
colours are derived: red, green and blue. The intensity of each of the channels range 
from 0 – 255 with 0 being the lowest to 255 being the highest intensity. Table 4.1 
shows how varying the intensity of each channel can change the final colour 
displayed. As the RGB model is additive, white is produced when all three channel 
are at maximum intensity (255, 255, 255) and black is produced when all channels 
are set to lowest intensity (0, 0, 0). 
Table 4.1 Actual colour represented by Intensity of each colour channel ranging from 0 – 255 in 
trichromatic RGB model 
R G B   Colour 
255 0 0  
0 255 0  
0 0 255  
255 255 255  
0 0 0  
 
To quantify the intensity of a colour, the corresponding channel value can be 
monitored, however, the single value alone may not be directly proportional to the 
intensity observed. This is due to the luminance of the object in the image. To 
illustrate this concept, two photographs of a blue coloured paper were recorded, one 
in bright conditions and one in darker conditions (i.e. one image has high luminance 
and one has low luminance). Using image processing software, the value of the blue 
channel in the bright image (170) was determined to be greater than in the darker 
image (150), despite the colour of the object remaining unchanged (Figure 4.9).  
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Figure 4.9 Digital photographs of blue coloured paper in dark conditions and light conditions  
 
Therefore, it is unsuitable to use only a single colour channel intensity as a measure 
of colour intensity without taking into account the luminance. One approach to 
overcome this is to measure the chromaticity of the colour which can be calculated 
as described in Equation 4.1: 
𝐶ℎ𝑟𝑜𝑚𝐵 =  
𝐵
𝑅 + 𝐺 + 𝐵
 
Where ChromB is the blue chromaticity, and R, G and B are the Red, Green and Blue 
channel values respectively.  
The sum of the R, G and B channels represents the total luminance of the image 
which can be used to obtain the intensity of a colour independent of the total 
luminance.  Taking the images from Figure 4.10 and comparing the ChromB value and 
the blue channel value it was found that the ChromB was a more accurate method of 
determining the intensity of the blue colour in both images as the ChromB values are 
much less affected by the luminance of the object (Table 4.2). 
Table 4.2 Comparison of methods to obtain blue colour intensity from two images of the same object 
in different light conditions. Error represents % Standard Deviation and n = 4  
Measurement Method Dark Lighting Bright Lighting 
Blue Channel Value 150.6 ± 2.10% 170.4 ± 0.71% 
ChromB 0.356 ± 0.25% 0.345 ± 0.15% 
  
Darker Conditions Brighter Conditions 
Equation 4.1 
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To validate the use of chromaticity in quantifying the blue colour intensity of  paper 
backplates, an experiment was carried out in which paper squares (1 cm2) were 
submerged in increasing concentrations of MB dye (0 – 1 mM) and allowed to air dry. 
Digital photographs of each square were taken and the ChromB values were 
calculated using ImageJ software. To control for any background interference, the 
ChromB values of paper squares that had been submerged in distilled water were 
subtracted from the readings. Figure 4.10 shows the linear relationship obtained 
between the ChromB and the MB concentrations (R2 = 0.95). From this experiment it 
was concluded that the ChromB could be used to quantify the intensity of the blue 
colour of a paper based sensor in response to glucose.  
 
Figure 4.10 Linear relationship between ChromB and MB concentration of paper squares after dye 
absorption and drying. Photographs of paper squares are shown to right of graph. Error bars represent 
standard deviation where n = 3 
 
4.3.5 Optimising the sensing system to produce a linear response to glucose in 
simulated ISF. 
In Chapter 3, the paper based glucose sensor was optimised to provide a rapid colour 
change in response to 10 mM glucose. In this section, the goal was to further optimise 
the sensor by establishing a linear colorimetric response to glucose concentrations 
between 0 – 10 mM in simulated ISF.  Using the previous ratio of enzymes to TMB 
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(850 U/L GOx, 170 U/L HRP, 3.33mM TMB), paper backplates were prepared and the 
colorimetric response to glucose concentrations within a 0 – 10 mM range were 
tested (Figure 4.11). The ChromB values of the backplates was used quantify the 
intensity of the colour change after 15 s. 
 
Figure 4.11 Plot of ChromB of glucose sensor embedded paper backplate 15s after direct addition of 
glucose solutions of increasing concentration. Error represents standard deviation where n = 3. 
 
The results from this experiment indicated that while there was a linear relationship 
between the glucose concentration and ChromB between 0 mM – 7.5 mM, at the 
higher concentrations of glucose (from 7.5 mM – 10 mM), a non-linear relationship 
existed due to the further oxidation of the blue charge transfer complex to form the 
yellow coloured diimine, as demonstrated previously in the UV/Vis studies in Section 
3.3.3. Therefore, in order to extend the linear response across a greater range of 
glucose concentrations, the concentration of the enzymes were decreased while the 
concentration of TMB was kept constant. Backplates were once again prepared but 
the concentration of GOx and HRP were decreased to 625 U/L and 125 U/L 
respectively. Several different concentrations of glucose (0 mM, 2.5 mM, 5.0 mM, 7.5 
mM and 10 mM) were added to the backplates and digital photographs of each 
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recorded at 1 s intervals for a total of 15 s and the ChromB values were calculated 
(Figure 4.12).    
The backplates rapidly began to change colour from white to blue as evidenced by 
the increase in the ChromB values, with the greater concentrations of glucose causing 
more intense colour change over the course of the 15 s, while the control backplate 
with the addition of blank PBS remained colourless. When the ChromB values at 15 s 
were plotted separately (Figure 4.13), a linear response was observed over the entire 
0 - 10 mM range. (R2 = 0.95). From the results of this experiment, backplates prepared 
using this concentration of enzyme and TMB were chosen to be paired with the 
hollow MN device to test the response to glucose after extraction using a similar in 
vitro experimental set up as in Section 3.3.4. 
Figure 4.12 Plot of ChromB against time for glucose responsive backplates following addition of 
increasing glucose concentrations. 10mM (Circle) 7.5mM (Square) 5mM (Triangle) 2.5mM (Inverted 
triangle) 0mM (Diamond). n = 3. Error bars are standard deviation. 
122 
 
 
Figure 4.13 Linear relationship between ChromB and glucose concentration after direction addition of 
5 µL of glucose between 0 – 10 mM in PBS.  
 
4.3.6 In vitro extraction of simulated ISF using MN device integrated with sensor 
backplate. 
Having demonstrated the ability of the hollow MN to transport fluid rapidly to a 
paper back plate, and having developed a suitable sensing system with a linear colour 
change over the 0 - 10 mM range, the next step was to incorporate both together 
and test the ability of the resulting device to measure glucose concentrations in 
simulated ISF. Briefly, a paper backplate embedded with the sensor was fixed to the 
upper side of the baseplate. The MN-backplate assembly was then pierced through 
a single layer of Parafilm and placed on top of PBS solutions spiked with varying 
concentrations of glucose between 0 – 10 mM as a surrogate for ISF (Figure 4.14). 
Photographs of each backplate were taken after 15 s and 30 s and the intensity of 
the colour change was analysed as before using ChromB measurements (Figure 4.15). 
R2 = 0.95 
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Figure 4.14 Schematic of the experimental set up of a glucose sensor embedded backplate attached 
to the single hollow MN device. The device was pierced through Parafilm to simulate the skin and 
place on top of PBS spiked with physiologically relevant concentrations of glucose (0 – 10 mM) as a 
surrogate for ISF 
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As was the case for the MB study, the MN-backplate assembly again rapidly withdrew 
the glucose solution as evidenced by a dampening of the paper backplate. In 
addition, the intensity of the blue colour generated 30 s following immersion was 
dependent on the concentration of glucose with excellent linearity (R2 = 0.99) 
observed over the 0 – 10 mM range. The relationship between the glucose 
concentration and the ChromB showed superior linearity after 30 s than at 15 s. This 
change may be due to the change in the volume of the glucose solution that is 
absorbed into the backplate in the in vitro setup where it is controlled by the capillary 
action through the lumen of the MN compared to the experiment in Section 4.3.4 
               0mM  2.5mM      5mM          7.5mM        10mM 
R2 = 0.99 
Figure 4.15 Digital photographs of sensor embedded backplates after 30 s showing blue colour change 
in increasing concentrations of glucose spiked PBS (above). Linear plot of ChromB against glucose 
concentration. Error bars represent standard deviation where n= 3 
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wherein a 5 µL aliquot of each glucose solution was added directly to the backplates. 
Representative images of the hollow MN-backplate assembly at each concentration 
demonstrated it was also possible to discriminate between the low and high glucose 
concentrations tested. Indeed, the difference in colour intensity produced from 
normal glycaemia (4 - 7 mM) and hyperglycaemia (>7 mM) was visually apparent. 
Direct 3D printing of MNs has been previously attempted153,154, however, one of the 
main limitations is the resolution of the printer, as observed in the work in this 
chapter. To overcome this issue, some groups have developed post printing 
processing steps such as chemical etching155 in order to reduce the tip size of each 
MN projection. While this method has demonstrated the ability produce polylactide 
MN arrays capable of penetrating porcine skin, it did result in non-uniform MNs with 
uneven surface morphology in comparison to MN produced by conventional MEMS 
technology. The method deployed in this chapter of using a hypodermic needle as a 
master template has resulted in the production of a sharp tipped, bevelled edge MN 
with a more uniform surface than those fabricated with chemical etching following 
direct 3D printing. 
Other efforts involving electrochemical detection of glucose within the ISF using 
enzyme coupled electrode systems have been previously published. Silicon dioxide 
MN arrays fabricated using photolithographic methods coupled to an enzyme linked 
biosensor has shown rapid uptake of ISF (1 µL/s) through capillary action in vitro and 
subsequent highly sensitive detection of glucose concentration across a range of 0 
mM – 35.0 mM156. 
Similarly, swellable poly (ethylene glycol diacrylate) MNs fabricated using 
photolithography have been doped with enzymes to create wearable electrodes to 
allow the detection of glucose and lactic acid concentrations157. However both 
systems have yet to be successfully demonstrated using in vivo models. 
4.4 Conclusion 
In conclusion, the results obtained in this chapter illustrate a novel method to 
manufacture a single hollow MN integrated with a colorimetric detection method for 
glucose. The hollow MN was formed by creating a master template with a 
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hypodermic needle coupled with a 3D printed housing that allowed replication of the 
needle tip and the hollow bore. The negative silicone mould was then used to create 
a solid photopolymer based MN device with a sharp bevelled tip to aid skin 
penetration, which demonstrated extremely rapid fluid uptake through capillary 
action within 5 seconds. The single MN projection withstood a mean axial load of be 
0.27 N ± 0.04 N before fracture, which is greater than the 0.028 N – 0.030 N per MN 
measured in other reports that is required for skin penetration.  
A method to quantify the intensity of the blue colour change in the sensor backplate 
was developed by calculating the ChromB values from digital images of the backplate 
after the addition of glucose. By altering the concentration of the components of the 
sensor system, a linear colour change after 30 s was achieved when the integrated 
MN device was used to extract physiologically relevant concentrations of glucose in 
simulated ISF in vitro. The colorimetric paper based backplate provided a rapid and 
facile method to detect glucose after 30 s that enabled discrimination between 
normal glycaemia (4 - 7 mM) and hyperglycaemia (>7 mM) with the naked eye.  
This integrated device obviates the need for removal and further processing of the 
simulated ISF from the MN to obtain a glucose concentration and thus represents an 
important step towards the goal of an easy to use, minimally invasive, POC device as 
an alternative to fingertip blood sampling in diabetes. The calculation of the ChromB 
was demonstrated to be an excellent method to quantify the intensity of the glucose 
dependent colour change. In the development of a colorimetric test strip for salivary 
glucose, Soni et. al158 demonstrated that an office scanner can be used to quantify 
the intensity of the colour change. Placing the test strip in the office scanner would 
control the lighting conditions of the strip during the data procurement, however, as 
demonstrated in Section 3.2.2, calculation of ChromB does control for changes in 
ambient light. Measurement of ChromB value using digital photography removes the 
need for the paper sensor to be separates from the MN and placed in the scanner to 
be measured and, therefore, it is more convenient and compatible to a wider range 
of experimental set-ups and devices. One could easily envisage the digital camera 
used in this chapter being replaced with a mobile phone with on-board imaging 
software making it even more user friendly.  
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The next step in the development of this approach would be to produce 2D arrays of 
hollow MNs. Fabrication of a 2D MN array would increase the mechanical properties 
of the device and, therefore, decrease the risk of MN breakage while also increasing 
the number of channels for ISF to be extracted through capillary action. Finally, while 
the polymer mix selected to manufacture the MN device was previously used to 
produce MNs151 and demonstrates excellent wettability properties, thus acts to 
extract fluid extremely rapidly through capillary action, the biocompatibility of the 
polymer mix would need to be investigated. 
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Chapter 5 
5.0 Glucose detection using a hollow metal microneedle interfaced with 
an optical glucose sensor: the use of antioxidants to modulate signal 
response. 
5.1 Introduction 
5.1.1 Hollow Metal MNs 
Biocompatibility is one of the key requirements of a transdermal device as they are 
designed to be in contact with both the skin surface and the upper layers of the 
epidermis. With the widespread use of silicon in MN manufacture using 
microelectromechanical systems (MEMS) technology, the biocompatibility of the 
silicon used has generated much interest. There is a risk of MN fracture upon 
insertion resulting in residual silicon remaining in the skin after use due to its brittle 
nature159. The presence of granulomas have been observed in response to the 
presence of silicon in the skin which is a sign of immune response and 
inflammation160. With the large range of immune cells present in the epidermis, the 
resultant release of cytokines and pro-inflammatory markers upon insertion of 
foreign bodies can elicit an immune response thus decreasing the biocompatibility of 
the material161.  
Metals such as stainless steel and titanium are commonly used in medical devices 
due to their mechanical properties and biocompatibility. Titanium has been used in 
prosthetics and implants162 whereas hypodermic needles are commonly 
manufactured from stainless steel. The use of stainless steel to make MNs has the 
advantage of both the mechanical robustness of the metal thus decreasing the risk 
of MN fracture upon insertion into the skin and the well-established biocompatibility 
of the material. Unlike hydrogel MNs which become unable to penetrate skin after a 
single use, metal MNs do carry the risk of accidental needle stick injury and as such 
may increase the risk of transmitting infection between users. However, due to the 
decreased length of the needle this risk may be quite low compared to full sized 
hypodermic needles as the shorter MNs are not capable of reaching the blood 
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capillary system in the skin and so are unlikely to directly carry blood borne 
pathogens from one person to another. Additionally, the risk of infection from 
microbes on the skin has been shown to be lower through the use of MNs compared 
to conventional hypodermic needles163,164. 
5.1.2 Modulation of the colorimetric glucose sensor for the detection of 
hyperglycaemia. 
In the previous chapter, a glucose responsive backplate was developed that 
produced a linear colour change to glucose concentration within 0 – 10 mM. While 
the intensity of colour change enabled differentiation between low physiological 
glucose concentrations (< 5mM) and high physiological concentrations (> 7.5 mM) 
using the naked eye, some ambiguity remains in distinguishing between different 
grades of colour intensity. A simpler approach would be an “Off-On” detection 
system that only produces a colour change when a certain level of glucose is 
exceeded.  Thus the sensor would remain colourless in normal glucose 
concentrations and give a colour change when the concentrations of glucose indicate 
hyperglycaemia (> 7.5 mM). 
From the work undertaken in Chapter 3 (see Section 3.3.3), it was observed that 
reducing the concentration of the GOx/HRP enzyme mix while maintaining the TMB 
concentration in the sensing system, reduced the rate of TMB oxidation when 
glucose was added. While further reductions of GOx/HRP could potentially result in 
the desired “Off-On” response to hyperglycaemia, the reduced enzyme 
concentration would reduce significantly the kinetics of the colour change reaction 
for it to be of practical use. Therefore, to achieve an “Off-On” colour change in 
response to hyperglycaemia within in a practically useful time, an alternative 
approach was necessary.  
Interference with GOx based colorimetric tests for glucose has been reported with 
strongly reducing substances including ascorbic acid (AA), beta-lactam antibiotics, 
levodopa, and salicylates giving false negative results165. AA has shown inhibitory 
effects in colorimetric assays for uric acid, cholesterol and glucose involving hydrogen 
peroxide mediated changes in colour intensity166. This is due to the high affinity of 
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AA for peroxidase enzymes causing depletion of the H2O2 produced as shown in 
Scheme 5.1. 
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Scheme 5.1: Peroxidase catalysed oxidation of ascorbic acid to dehydroascorbic acid by hydrogen 
peroxide  
 
Clinistix reagent strips are a commonly used paper based colorimetric test for urine 
glucose that is based on the oxidation of o-tolidine in a GOx/HRP enzyme system. AA 
has been shown to cause a delay in the formation of the coloured compound that 
was proportional to the concentration of the AA (Table 5.1). Additionally, at 
increasing concentrations of glucose the resultant lag phase was decreased167.  
Table 5.1: Inhibition of colour change in Clinistix glucose test strips in the presence of AA 167 
 Time lag (s) at glucose concentration of : 
Ascorbate (mg/L) 2.5 g/L 5 g/L 7.5 g/L 
100 2 - - 
250 4 3 3 
500 7 5 4 
1000 22 9 7 
 
Similarly, using a 4-aminophenazone based dye which combines with phenol to form 
a quinoneimine in the presence of H2O2 (Figure 5.1), a delay in colour formation is 
observed when AA was added to the dye system155.  
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Figure 5.1 Trinder reaction, a H2O2 dependent formation of coloured quinoneimine dye used to 
determine glucose concentration1  
As both the ascorbic acid and dye compete for the available peroxide, oxidation of 
the dye and concomitant colour change is inhibited or delayed.  Thus, when 
monitoring the development of the coloured chromophore, a time delay form the 
start of the reaction is observed in which no visible coloured compound is generated. 
This delay or lag phase has been found to be proportional to the concentration of the 
ascorbic acid concentration and inversely proportional to the concentration of 
glucose1.  
This lag phase may be exploited in order create a sensor to produce a colour change 
within a predetermined time period only if the concentration of glucose was high 
enough, thus indicating hyperglycaemia. In lower glucose concentrations, the lag 
phase would be increased and, therefore, no colour change would occur within the 
predetermined time period. 
5.1.3 Vacuum assisted suction through MNs 
MNs coupled with vacuum force have been used previously to extract ISF from the 
skin. However, they have largely involved piercing the stratum corneum with solid 
MN arrays followed by the application of a separate vacuum device to draw fluid 
through the micropores created after the MN array was removed168. In this chapter, 
a flexible housing for the hollow MN device was designed in order to aid the 
extraction of fluid. The integrated housing generated a small negative pressure 
created by the press and release of the housing to draw fluid through the MN and 
into the sensor backplate. 
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5.2 Aim and Specific Objectives 
The main aim of the work undertaken in this chapter was to manufacture a hollow 
MN device with the MN projection composed of stainless steel coupled with a paper 
based sensor that underwent a colour change only in high concentrations of glucose 
that indicated hyperglycaemia. The specific objectives were: 
i. Manufacture of a hollow metal MN device that can extract fluid rapidly 
and transport it into an attached backplate. 
ii. Development of a colorimetric sensor based on GOx/HRP, TMB and 
ascorbic acid to indicate hyperglycaemic concentrations.  
iii. Investigate the benefit of incorporating vacuum assisted suction within 
the MN housing to facilitate rapid solution withdrawal. 
iv. Integration of the paper based sensor backplate with the hollow MN 
device and subsequent in vitro testing to investigate its ability to rapidly 
indicate hyperglycaemic concentrations in simulated ISF. 
 
5.3 Results and Discussion 
5.3.1 Manufacture of Hollow Metal MN device 
 BD Micro-fine Ultra 32G needles were used to create the metal hollow MN device. 
The commercially available needles possessed a bevelled edge on each end. 
However, each side was not identical as demonstrated by the optical microscope 
image below (Figure 5.2). The end designed to pierce the skin to a depth of 4 mm 
possessed a bevel 1100 µm ± 12 µm in length. Therefore, it was not possible to use 
the full length of this end in the MN as the final projection would extend longer than 
1000 µm. The opposite end of the 32G needles had a bevelled end 417 µm ± 5 µm in 
Figure 5.2 Light microscope image showing both ends of a BD Micro-fine Ultra 32G needle. Scale bar is 
200 µm in both images 
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length. This enabled inclusion of the total length of this bevelled end and an 
additional portion of the needle shank to yield a final MN projection within the 1000 
µm limit.  
Initially, attempts were made to cut the needles to the desired length (i.e. 2 mm) 
using pliers but this resulted in the end of the needles being closed due to the 
compression from the pliers.  To circumvent this issue, the needles were cut to 
approximately 4 mm in length and then inserted in a custom made holder (Figure 
5.3).  
 
Figure 5.3 Custom holder used to reduce needles to correct length while remaining open. (Left) 
Baseplate into which top plate is placed. (Right) 2 mm deep upper plate with 4 circular holes (white 
arrows) 200 µm in diameter into which the needles are placed point downwards. 
 
The holder consisted of a baseplate with an upper plate 2 mm in depth attached 
together with screws. In the upper plate, holes were drilled using a drill bit which was 
100 µm in diameter. The 4 mm long needles were inserted into these holes with the 
needle point downwards and the excess material was filed away using abrasive wet-
or-dry sand paper (Figure 5.4).  
134 
 
 
Figure 5.4 Schematic diagram of needle placed point downwards into 200 µm diameter holes in needle 
holder. Needle is reduced in length by circular sanding until level with the surface of upper plate which 
yielded 2 mm long needles  
 
Initially grade P600 paper was used to remove the majority of the excess length of 
the needle then grade P1000 paper was used to remove the final ~0.5mm in order to 
remove small burrs in the metal walls of the needle and ensure the plastic holder was 
not substantially abraded. After removal from the holder the needles were washed 
in acetone to remove metal debris and a length of stainless steel wire (100 µm 
diameter) was inserted through each needle to ensure complete opening. Figure 5.5 
shows how the needle end that was closed after cutting with the diagonal cutting 
pliers was reopened using the sanding method.  
 
Figure 5.5 (Left) Photograph of needle cut with diagonal pliers showing how the end of the needle is 
crimped closed. (Right) Photograph of needle after sanding showing the reopening of the needle 
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A baseplate in which to house the 2 mm needle was created using a silicone moulding 
technique. As described in detail in Section 2.4.2, a master mould was designed in 
CAD and created using the Form 1+ 3D printer in the proprietary clear methacrylate 
based photopolymer. The master mould was used to make a negative mould using 
RTV silicone. The 2 mm hollow needle was placed in the centre of the negative mould 
and the MN baseplate, composed of TRIM, was polymerised around its base, leaving 
the needle tip exposed. An aliquot of 200 µL of TRIM was pipetted into the silicone 
mould before irradiation with 365 nm UV lamp for 60 mins (Scheme 5.2). 
After polymerisation, the MN with attached baseplate was removed from the mould, 
washed in ethanol and dried at 60 °C for 10 min. A representative photograph of the 
prepared MN is shown in Figure 5.6a and clearly reveals the crosslinked TRIM 
polymer baseplate with a single MN projection emerging. The bevel end of the 
needle was clearly hollow and emerged through the base plate to the other end. In 
addition, Figure 5.6b also clearly demonstrates the photopolymer coats the needle 
shank maintaining it in place and providing mechanical strength. In total, 10 MN were 
produced using this method with a mean MN projection of 590 µm ± 23 µm. 
 
Scheme 5.2 Photo-catalysed polymerisation of TRIM by free radical generator 1-Hydroxycyclohexyl 
phenyl ketone (Irgacure 184) and UV irradiation (365nm) 
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5.3.2 Flexible PDMS suction housing to aid fluid extraction  
In Chapter 4, the MN device prepared relied solely on capillary action to draw fluid 
through the MN opening and into the backplate. While the liquid extraction kinetics 
using this method was rapid, this was determined in solution and does not accurately 
represent tissue where the volume of ISF is not as large or readily accessible. To 
overcome any possible reduction in fluid withdrawal rate as a consequence of these 
issues, a modified housing for the MN device was also developed. The housing was 
prepared from PDMS in order to provide a suction force to draw fluid though the 
metal MN. The attachment was designed to be flexible enough to be slightly 
deformed when pressed with the fingertip as the MN was being applied. In this way, 
when the finger was released, the PDMS attachment would revert to its original 
shape and create a suction force through the metal MN, thus drawing fluid into the 
backplate. To create this attachment, a master mould was created using CAD and 
printed using the Form 1+ in clear resin as before (Figure 5.7). The mould was 
designed to allow the replication of an optically clear PDMS housing for the hollow 
MN device. The resultant square shaped housing with each side 15 mm2 in length, 
with a depth of 6 mm and possessed a square opening for the MN device itself with 
each side measuring 10 mm2 long. 
Figure 5.6 (a) Photograph of metal hollow MN in polymer baseplate. (b) stereomicroscope image of 
MN. Scale bar is 250 µm  
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Figure 5.7 (Left) CAD image of master mould for PDMS suction device (Right) Photograph of mould for 
PDMS housing created using 3D printer.  
In order to create a sufficient seal with the baseplate of the metal MN, the PDMS 
housing was designed with a segment of material that protruded from the length of 
the inner edge, as indicated in Figure 5.8. This design element was found to be an 
effective method to hold the square baseplate in place while it was fixed with 
adhesive. The assembled device with a blank paper backplate is shown in Figure 5.8.  
 
Figure 5.8 (Left) PDMS housing created from master mould. Arrow depicting inner edge used to hold 
polymer baseplate in place. (Right) Photograph of assembled device consisting of hollow metal MN in 
the polymer baseplate adhered to the PDMS attachment    
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Figure 5.9 shows the steps involved in the operation of the assembled MN device. 
The MN will be applied in order to pierce the metal hollow MN through the 
membrane to gain access to the glucose solution. Depression and subsequent release 
of the flexible PDMS housing by gentle finger pressure creates a negative pressure 
within the MN device that will aid fluid extraction through the hollow MN and into 
the sensor backplate for analysis.  
In order to test the capability of the metal MN device with the PDMS attachment to 
withdraw fluid through suction, 30 mL of a 1 mM methylene blue dye was added to 
a petri dish. Two glass slides were placed lengthways across the top of the dish and 
separated by a gap of 5 mm to act as a solid support. The assembled metal MN 
device, shown in Figure 5.8, was then pierced through a layer of parafilm and placed 
on the petri dish in such a way so as the MN was in contact with the methylene blue 
dye between the glass slides (Figure 5.10). The flexible PDMS attachment was then 
depressed with thumb pressure and released. It was observed that a small volume of 
methylene blue dye was drawn up through the MN and into the backplate reservoir 
containing a blank paper square confirming the feasibility of the device.  
 
Figure 5.9 Schematic of the operation of the PDMS housing and single hollow MN device 
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Figure 5.10 Schematic of experimental set up to investigate the capability of the MN device to draw 
Methylene blue solution from the container through the MN and into the paper backplate. The glass 
slides were in place to provide a solid support to allow the flexible PDMS attachment to be pressed 
and released.  
 
As demonstrated in Figure 5.11, photographs taken 5 s following release of thumb 
pressure reveal successful extraction of a small volume of MB solution that had been 
absorbed rapidly by the paper backplate. This demonstrated that the suction 
pressure generated from the press and release of the PDMS housing was sufficient 
to cause the movement of the MB solution from the MN tip, through the hollow MN 
and into the paper backplate, contained within the assembled device. 
 
 
 
 
 
 
 
 
 
Figure 5.11: Photograph of assembled hollow MN device 5 s after press and release showing 
extraction of MB solution into black paper backplate 
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It was noted that although the blue colour could be observed through the PDMS 
attachment, the PDMS material was not completely optically clear. This was due to 
the uneven surface of the mould that is inherent to the 3D printing technology and 
the polymer material used to create the mould. This resulted in the PDMS having a 
slightly uneven inner surface which led to the light becoming diffuse as it passed 
through, resulting in a blurred image. To overcome this, the mould was modified 
slightly by placing a glass microscope coverslip to the uneven mould surface in the 
visualising region of the backplate. (Figure 5.12). 
 
Figure 5.12 Cross sectional CAD images of mould used to create PDMS attachment. (Left) Original 
mould. (Right) Mould with added glass slide layer. 
 
The glass slide provided a smooth surface for the curing of the PDMS and resulted in 
much more optically clear polymer window through which the colour of the paper 
could be observed. To demonstrate this, paper squares were spotted with a small 
volume (~2 µL) of methylene blue solution and photographed when placed in the 
non-modified PDMS housing or the modified glass slide PDMS housing. A photograph 
of the same paper square without the presence of a PDMS housing was taken for 
comparison (Figure 5.13).  
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Figure 5.13 Representative photographs of the same paper backplate with methylene blue dye stain 
as seen through different PDMS attachments. (a) No PDMS housing. (b) Non-modified PDMS housing. 
(c) PDMS housing with glass slide modification. 
 
While this modification to the mould created a more transparent PDMS housing 
through which to see the colour of the paper backplate than the original PDMS 
housing, the photographs were also analysed using ImageJ and the blue chromaticity 
of the methylene blue dye spots were calculated for comparison (Figure 5.14). 
 
Figure 5.14 Plot of ChromB of paper backplate with methylene blue as seen through original non-
modified PDMS housing and PDMS housing created with glass cover modified mould. Control is paper 
backplate imaged with no PDMS housing. ** p < 0.01. (n = 3) 
 
The mean ChromB value of the paper backplate with no PDMS housing was 0.118 ± 
0.011. When photographed through the modified PDMS housing the ChromB value 
was 0.102 ± 0.008 which is comparable to the control and was significantly greater 
(a) (b) (c) 
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than the non-modified PDMS housing (0.074 ± 0.004, p < 0.01). These representative 
photographs and quantification of the ChromB values demonstrate the benefit of the 
modified PDMS housing compared to the original housing with a clearer observation 
of the colour change to the end user of the device. 
 
5.3.3 Optimising the GOx/HRP, TMB based colorimetric sensor using ascorbic acid to 
modulate the glucose mediated colour change 
L-Ascorbic acid (AA) is oxidised by H2O2 to dehydro-L-ascorbic acid through a 
reversible two electron mechanism with a free radical intermediate (Scheme 5.1). 
Further oxidation into diketogulonic acid and tetrahydroxydiketohexanoic acid has 
also been reported169. 
To investigate the effect of AA on the H2O2 producing glucose sensor developed in 
the previous chapters, photophysical studies using the glucose sensor system with 
AA added were undertaken. Subsequent changes in the TMB intensity at 650 nm was 
determined by UV/Vis spectroscopy. Solutions containing GOx, HRP and TMB were 
prepared using the optimised ratios for a rapid linear glucose mediated colour 
change (625 U/L GOx, 125 U/L HRP and 3.33 mM TMB) as determined in Section 
4.3.4. These solutions also contained either (0 µM, 20 µM or 40 µM) AA which were 
the initial concentrations chosen to observe the effect on the generation of the 
coloured TMB compound. 5 µL aliquots of 7.5 mM and 10 mM glucose were then 
added to each solution and the absorbance at 650 nm measured every 10 s for 5 min. 
A plot of absorbance intensity at 650nm as a function of time was plotted for each of 
the three experiments and is shown in Figure 5.15.  In the solution containing no AA 
(Figure 5.15a), the oxidation of the TMB proceeded immediately after the glucose 
was added, with the 10 mM glucose experiment showing a higher rate of oxidation 
than the 7.5 mM glucose experiment, consistent with the results obtained in Section 
4.3.4.  When 20 µM AA was added to the sensor system, the kinetics of the reaction 
changed significantly (Figure 5.15b), with an initial period where the TMB was not 
oxidised, as demonstrated by no substantial change in the absorbance from the 
baseline in the initial 10 s. This delay in intensity increase lasted longer (50s) for the 
7.5 mM glucose experiment than for the 10 mM glucose experiment (20s), consistent 
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with the hypothesis that more glucose generates more peroxide that oxidises AA in 
preference to TMB.  
The results in Figure 5.15c show that the effects of the AA on the kinetics of the 
reaction were more pronounced as the concentration was increased. The 10 mM 
glucose solution started to increase from the baseline at 30 s and the 7.5 mM glucose 
solution increased at 90 s.  This demonstrated that the lag phase could be increased 
by including more AA within the sensor system.  
The results of these experiments demonstrated that AA could be used to modify the 
glucose sensor to give a blue colour change only in hyperglycaemic conditions within 
a given time period, for example within 60 s. A time constraint had to be specified as 
the inclusion of AA did not stop the colour change reaction from occurring in normal 
glucose concentrations, however, it did introduce a substantial lag phase before a 
colour change occurred between  a 10 mM glucose sample (hyperglycaemia) and 7.5 
mM (normal glucose).  
 
   )  
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Figure 5.15 UV/Vis spectra of oxidation of TMB by GOx/HRP in solutions containing several 
concentrations of AA. Absorbance was measured at 650 nm at 10 s intervals. Circles represent 
solutions spiked with 10 mM glucose. Squares represent 7.5 mM glucose. Error bars are standard 
deviation (n = 3) (a) No AA (b) 20 µM AA (c) 40 µM AA 
(a) 
(b) 
(c) 
145 
 
5.3.4 Glucose sensor embedded backplates with ascorbic acid to indicate 
hyperglycaemia  
Following the solution experiments described in Section 5.3.3 that used UV-Vis 
spectroscopic detection, the next step was to determine if a similar effect occurred 
when the AA modified sensor was incorporated into paper backplates. The 
concentrations of the sensor and AA optimised in the UV-Vis experiments were not 
directly translatable to the paper backplates due to the way the backplates were 
prepared. For example, as the backplates were dried following immersion in sensor 
solution, the addition of a small volume of glucose solution (1 µL) to the backplate 
modifies the concentration of both the sensor and AA. Therefore, the quantities of 
sensor and AA used to create the paper backplates had to be determined 
experimentally using the paper backplates, rather than using the concentrations 
determined in the UV-Vis experiments. 
Sensor backplates were prepared as previously described (Section 2.2.7). To add the 
AA to the backplates, the paper squares embedded with the enzymes and TMB were 
allowed to dry for 60 mins at room temperature before being submerged in aqueous 
solutions of AA at the following concentrations – 0 mM, 2.5 mM, 5.0 mM, 7.5 mM, 
10 mM, then dried at RT for 60 mins.  
60 s was chosen as the measurement time to indicate hyperglycaemic conditions as 
this would provide results in a timely manner in a POC device.  The backplates were 
tested using glucose concentrations of 10 mM and 7.5 mM as these were the key 
concentrations in hyperglycaemia ( > 7.5 mM), therefore 1 µL aliquots of each glucose 
concentration in PBS were added to each backplate and a photograph of each was 
recorded after 60s (Figure 5.16)  
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Figure 5.16 Photographs of paper backplates with embedded TMB and GOx/HRP sensor systems. A 
range of concentrations of AA (0 mM – 10 mM) were added to each backplate. Photographs were 
taken 60 s after 1 µL aliquots of either 10 mM or 7.5 mM of glucose were added to each backplate 
 
After 60 s, the most intense colour change was observed in the control (0 mM AA) 
backplates for both concentrations of glucose. Similarly, both concentrations of 
glucose resulted in a colour change in the 2.5 mM AA backplates, although these 
were less intense than the control backplates. In contrast, only the hyperglycaemia 
concentration (10 mM) showed a colour change in the 5.0 mM AA backplate while 
the normal glycaemia (7.5 mM) gave no colour change. Notably, the colour change 
in the hyperglycaemia concentration in the 5.0 mM AA backplate was less intense 
than either the control or 2.5 mM AA backplates. No colour change was observed for 
either glucose concentration in the 7.5 mM or 10.0 mM AA backplates. These results 
can be explained through the inhibitory effect of the AA causing a longer lag phase 
before the TMB oxidation takes place. The more AA there is available to react with 
the hydrogen peroxide generated, the longer it takes for the TMB to become oxidised 
and any colour change to be realised.  Based on the results shown in Figure 5.16 
above, 5mM AA containing sensor backplates produced the optimum result as no 
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colour was obtained within 60 sec in 7.5 mM glucose solution while a visibly apparent 
blue colour was observed for the 10 mM glucose solution, clearly differentiating 
between normal and hyperglycaemic concentrations of glucose.  .   
These 5.0 mM AA backplates were then tested using a wider range of glucose 
concentrations to mimic the clinically relevant measurements in diabetes. 4.0 mM 
and 7.5 mM glucose solutions were included to mark the lower and upper bounds of 
the normal range of glucose in the blood. 10 mM and 20 mM were used to represent 
hyperglycaemia. 1 µL aliquots of these glucose solutions were pipetted on to the 
backplates in triplicate and photographs were recorded at 60 s intervals for 5 mins. 
A representative image of each time point is shown in Figure 5.17. 
 
Figure 5.17 Photographs of sensor backplates containing TMB, GOx/HRP and 5 mM AA. Image taken 
at 60 s intervals after 1 µL aliquots of a range of concentrations of glucose were added to each 
backplate (0 mM – 20 mM) 
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For the 0 mM glucose, no colour change was generated over the course of the 
experiment. When 4.0 mM glucose was added no colour developed until a faint blue 
spot appeared after 300 s. The upper limit to normal glycaemia (7.5 mM glucose) 
caused no colour change at 60 s however at 120 s a coloured spot was generated that 
further developed throughout the remainder of the experiment. The first 
hyperglycaemia concentration of 10 mM glucose developed a coloured spot within 
60 s that remained thereafter. Similarly, the, 20 mM glucose solution produced a 
coloured spot at 60 s that further developed until the end of the experiment. 
As can be observed from the images in Figure 5.17, the colorimetric response to 
glucose produced both blue and yellow coloured spots depending on the progress of 
the reaction and as a consequence, the oxidised species generated. Therefore, 
quantifying blue chromaticity alone would not accurately reflect the reaction kinetics 
by proving a low reading for a reaction that has already progressed through the blue 
single oxidation product to the yellow di-oxidised product.  By converting the images 
to grayscale, the intensity is less dependent on the type of colour but more by the 
intensity. Therefore, the images at each time point in Figure 5.17 were converted to 
an 8-bit grayscale image using ImageJ170 (Figure 5.18a).  The mean gray values of the 
coloured areas of each backplate were then obtained and the intensity of colour was 
calculated using Equation 5.1: 
Intensity (a. u. ) = 255 − Mean Gray Value   Equation 5.1 
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Figure 5.18 (a) Grayscale image of backplates from Fig. 5.14 (b) Plot showing the intensity of the colour 
change in each backplate at 60 s intervals in response to addition of glucose solutions (0 mM – 20 
mM) 
(a) 
(b) 
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As can be observed in Figure 5.18b, the intensities of the coloured spots correlated 
to what was observed by the naked eye with the 0, 4 and 7.5 mM glucose solution 
producing intensities that were low at 60s, while the 10 and 20 mM intensities 50-
fold higher at the same time point. Again, these results suggest that using 5.0 mM 
AA within the backplate and identifying a time–point of 60 s following application of 
the MN should be appropriate to discriminate between normal and hyperglycaemic 
conditions.    The next step was to interface the AA containing sensor backplate with 
the suction-assisted MN device and determine how effective this would be at 
discriminating glucose concentrations following extraction of glucose from simulated 
ISF. 
5.3.5 Incorporation of Ascorbic acid modified sensor backplate with hollow MN device 
for the Off-On detection of hyperglycaemia in simulated ISF.  
Sensor backplates containing 5 mM AA were prepared as described in Section 2.4.5 
and fixed onto the base plate of the hollow metal MN. The MN-sensor construct was 
then incorporated within the flexible PDMS housing and sealed using adhesive as 
described in Section 2.4.3. The same in vitro model as described in Section 5.3.2 was 
used to simulate penetrating the skin with thumb pressure used to provide vacuum 
and facilitate extraction of the glucose solutions via suction. The experiment was 
repeated in triplicate. Glucose concentrations (0 mM, 4 mM, 7.5mM, 10 mM and 20 
mM) in PBS buffer were used as simulated ISF and in each case photographs were 
taken at 30 s intervals for 120 s. Representative images are shown in Figure 5.19. 
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Figure 5.19 Photographs of sensor backplates in the assembled metal MN device after extracting 
glucose solutions (0 mM – 20 mM) at 30 s intervals  
 
The MN device successfully extracted the glucose solutions though the metal needles 
and into the paper backplates as evidenced by the wetting observed on the sensor 
backplates. The MN that extracted the control solution (0 mM glucose) did not 
produce any colour on the backplate. Similarly, the 4.0 mM glucose solution did not 
produce a colour response within the time-scale of the experiment (120 s). The upper 
range of normal glycaemia (7.5 mM glucose) did not produce a colour change 
between 0 – 60 s, however a faint blue spot was observed at 90 s which further 
developed to a more visually apparent yellow colour at 120 s. The first 
hyperglycaemic concentration of 10 mM glucose caused no colour change at 30 s but 
the backplate had developed a strong colour change by 60 s, which increased in 
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intensity throughout the course of the experiment. The highest concentration of 
glucose (20 mM) caused the most rapid colour change, with a readily visible coloured 
spot observed at 30 s which had increased in intensity at 60 s and remained through 
to the end of the experiment. As before, the images were converted to 8 bit 
grayscale. The intensity at 60 s were measured and are shown in Figure 5.20. 
Figure 5.20 Plot showing the intensity of the colour change at 60 s in the sensor backplate in Fig 5.19 
in response to the extraction of glucose solution using assembled MN devices (0 mM – 20mM) (n=3) 
* denotes p < 0.05 for intensity generated between 10 mM and 0 mM control and 20 mM and 0 mM 
control 
 
At 60 s, there was no significant difference between the grayscale values of the 0 
mM, 4.0 mM and 7.5 mM glucose solutions. This demonstrated that normal 
glycaemic concentrations did not cause a colour change within 60 s in the assembled 
device.  However, there was a significant increase in intensity for the 10 mM glucose 
solution when compared the 0 mM control (p < 0.05) and the increase in intensity for 
the 20 mM glucose when compared to the control (p < 0.05) at the same time point.  
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These results confirm that the device successfully indicates hyperglycaemic levels of 
glucose when the device is applied to the glucose solution for 60 s, with a colour 
change that is easily visible by the naked eye.  
A MN device consisting of an in-plane array of hollow metal needles has 
demonstrated successful extraction of ISF in human volunteers171.  The metal needles 
used in the fabrication of the device were also BD 32G pen needles as in this chapter, 
however the opposite longer bevelled end of the needles were used. This resulted in 
the production of MNs of 1000 µm, 1500 µm and 2000 µm height, which were 
substantially greater than the 600 µm MN reported in this chapter. The hollow MNs 
were fabricated using a CO2 laser cutter to control the MNs length and surrounding 
plastic housing. Glass capillary tubes were attached to the opposite end of each MN 
to act as a reservoir for the extracted ISF. Using a MN array consisting of five MNs in 
parallel, up to 16 µL of ISF was extracted from 14 human volunteers after a lag time 
of 30 - 120 s. The ISF collected in this study was used to determine transcriptome, 
proteome and exosome content and while it was acknowledged that ISF could be 
used to quantify glucose, no measurements have been reported using this device172.  
The crucial design aspect of this MN that allowed the successful ISF extraction was 
the concentric circular plastic ring of the housing around the opening of each MN. 
This concentric ring allowed the skin under the MN opening to remain uncompressed 
upon MN penetration. The authors assert that the pumping mechanism from the 
compression of the skin under the concentric ring of plastic to the uncompressed skin 
under the MN tip induced ISF to flow into the MN opening and into the reservoir. 
This design aspect could be incorporated in to the proposed device in this chapter if 
necessary to aid the extraction of ISF following in vivo investigations. 
5.4 Conclusion 
The results obtained in this Chapter demonstrate the use of a hollow metal MN 
device that can successfully extract simulated ISF in vitro and indicate the presence 
of hyperglycaemia within 60 s through a colour change. The detection of 
hyperglycaemia using a paper based sensor that is integrated into the MN device 
without the requirement for subsequent spectroscopic or chromatographic methods 
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is a novel approach. An additional novel aspect of this work was the use of AA to 
create a sensor that can discriminate relatively small differences in glucose levels 
through a visually apparent and non-ambiguous colour change using commercially 
available reagents without the need for complex synthetic routes and purification 
steps. The peroxide sensitive AA inhibited the formation of the coloured TMB 
product in physiologically normal concentrations of glucose (4 mM – 7.5 mM) within 
60 s. However in higher concentrations, the generated peroxide overcame the action 
of AA and oxidised the TMB into its coloured product to give a colour change as an 
indication of hyperglycaemia (>7.5 mM glucose) at 60 s. 
The device utilised stainless steel hollow needles due to their excellent mechanical 
properties and favourable biocompatibility profile, thus reducing the risk of MN 
fracture and skin sensitisation, often reported when using polymeric and silicon 
based MNs. Using 3D printing technology and silicone moulding, a PDMS attachment 
was coupled to the metal hollow MN that allowed the generation of a negative 
pressure upon the application of the MN that aided the extraction of ISF through the 
MN and into the paper based sensor backplate.  
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Chapter 6 
6.0 Conclusions and Future Outlook 
The work in this thesis has investigated MN based extraction and subsequent 
colorimetric determination of glucose within simulated ISF, in order to provide a 
minimally invasive method of indirectly monitoring glycaemia in the blood. Both 
hydrogel MNs and hollow MNs fabricated from methacrylate based polymers and 
stainless steel were used to provide a rapid means of extracting the simulated ISF 
and bringing it into contact with the glucose sensor. The enzyme based sensor was 
developed to generate a colour in response to glucose concentration and could be 
optimised to give a linear colorimetric response to quantify the concentration of 
glucose or provide an Off-On switch only sensitive to hyperglycaemic levels.  
Crosslinked PMVE/MA MNs have previously shown the ability to extract ISF in human 
subjects and the work in Chapter 3 has successfully demonstrated the integration of 
a sensor embedded backplate to these MNs that gives a visually apparent blue colour 
change in the presence of glucose. One of the main limitations of this approach in its 
current form was the time taken for the ISF absorb into the MN and move into the 
sensor backplate to interact with the sensor. It has been shown that using a paper 
based sensor backplate and increasing the length of the MN projections caused the 
response time to significantly decrease in vitro, however for use in a POC device 
future development should seek to lower the response time further.  
A single hollow MN device in Chapter 4 showed the ability to rapidly extract 
simulated ISF and move it into the sensor backplate within 5 s using capillary action 
in vitro, thus demonstrating a major improvement in the response time. The sensor 
was also optimised to provide a means of quantifying the concentration of glucose 
within the simulated ISF through the use of a digital camera. While larger differences 
in glucose concentrations, for example between hypoglycaemic conditions and 
hyperglycaemic conditions were visually apparent, further work could allow smaller 
changes to be measured using a smartphone camera and a calibration colour chart. 
Other development opportunities may include increasing the number of hollow MN 
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projections to produce a 2D array for superior mechanical robustness and to provide 
additional channels to extract ISF.  
Finally, Chapter 5 has detailed the production of a single metal hollow MN coupled 
to a flexible housing to provide ISF extraction through both capillary action and 
suction. The sensor was modified to give an Off On switching mechanism to identify 
hyperglycaemic concentrations in a visually apparent way that could find use to 
screen larger populations without the need from blood extraction or to alert 
diabetics to periods of hyperglycaemia that would then require administration of 
insulin or other hypoglycaemic agents. Future improvements could involve tailoring 
the sensor for the detection of hypoglycaemia. One potential method of achieving 
this would be to determine the time taken for the sensor to change colour when the 
glucose is in the hypoglycaemic range and use this as time point as a marker, i.e. if 
no colour change is visible before this time point then hypoglycaemia is present. 
In summary, a MN based approach to measuring ISF analytes has enormous potential 
to avoid the current issues with blood sampling, such as contamination with blood 
borne pathogens, reduction of needle stick injuries and increasing patient 
compliance due to convenience and decreased pain. This work demonstrates 
promising methods to extract ISF rapidly and the integration of colorimetric sensors 
for glucose to aid in the development of POC devices.  
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